SOUTHAMPTON JOINT FORMULARY
CUMULATIVE UPDATE
This document is a cumulative list summarising changes to the Southampton Joint Formulary. To check the current status of a medicine please refer to www.southamptonformulary.nhs.uk
Date Drug and formulation Colour BNF Comments Action status section
3/2/2020 Medroxyprogesterone Green 7.3.2.2 Sayana Press brand added Amend acetate [Depo- as an alternative option Provera/Sayana Press] (useful for women who wish to self-administer – see primary care guidance here). 3/2/2020 Clonidine 50 micrograms Red 2.5.2 Restricted– only for short- Add in 5ml oral solution term, off label use in sedation/opioid withdrawal in high care paediatrics in accordance with UHS protocol; oral solution for use only when tablet formulation not suitable 3/2/2020 Olaparib capsules/tablets Red 8.1.5 Olaparib for maintenance Amend treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation. For use within the Cancer Drugs Fund. Replaces NICE TA381. Note: only the ‘tablets’ formulation are covered by this TA and TA598 (capsules are due to be discontinued) 3/2/2020 Lusutrombopag tablets Red 9.1.4 NICE TA617: Add [Mulpleo] Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. 3/2/2020 Cladribine capsules Red 10.2 NICE TA616: Cladribine for Amend [Mavenclad] treating relapsing–remitting multiple sclerosis. Replaces NICE TA493 3/2/2020 Cannabidiol 100mg per Red 4.8.1 Registered specialist only. Add ml oral solution NICE TAs614 and 615: [Epidyolex] Cannabidiol with clobazam for treating seizures associated with Lennox– Date Drug and formulation Colour BNF Comments Action status section
Gastaut syndrome and Dravet syndrome
3/2/2020 Palbociclib capsules Red 8.1.5 NICE TA619: Palbociclib with Amend [Ibrance] fulvestrant for treating HR- positive, HER2-negative, advanced breast cancer. For use within the Cancer Drugs Fund. Blueteq registration required. 3/2/2020 Cycloserine capsules Red 5.1.9 Specialist microbiology/TB Add service recommendation only. (For use in accordance with WHO Guidelines for multi drug-resistant tuberculosis). 3/2/2020 Clofazimine capsules Red 5.1.9 Unlicensed. Add Specialist microbiology/TB service recommendation only. (For use in accordance with WHO Guidelines for multi drug-resistant tuberculosis). 3/2/2020 Diltiazem prolonged- Blue 2.6.2 Cost effective alternative Add release capsules brand for use in primary [Zemtard XL] care. 3/2/2020 Diltiazem prolonged- Green 2.6.2 Amended from blue to Amend release capsules [Viazem green. XL] This will now be the brand of choice at UHS. 3/2/2020 Diltiazem prolonged- Green 2.6.2 Discontinued by Remove release capsules manufacturers [Slozem] 3/2/2020 Zanamivir inj [Dectova] Red 5.3.4 For treatment of complicated Add and potentially life- threatening influenza A or B virus infection in accordance with official guidance. 3/2/2020 Fluticasone/umeclidinium Green 3.2 Amended from amber to Amend /vilanterol DPI [Trelegy green. Ellipta]
3/2/2020 Beclometasone/formotero Green 3.2 Amended from amber to Amend l/glycopyrronium MDI green. [Trimbow] 3/2/2020 Buprenorphine oral Amber 4.10.3 Not initiated in UHS. Add lyophilisate tablets Note: this brand is not [Espranor] interchangeable with other buprenorphine products. Date Drug and formulation Colour BNF Comments Action status section
18/12/19 Histidine, tryptophan, Red 9.2.2.1 Restricted – for specialist Add ketoglutarate perfusion cardiac surgery use only. Off solution [Custodiol] label use for administration into renal arteries as renal protection during open thoracoabdominal aortic aneurysm repair surgery. Solution is classed as a medical device – CE marked. 18/12/19 Rucaparib tablets Red 8.1.5 NICE TA611: Rucaparib for Add [Rubraca] maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer 18/12/19 Neratinib tablets Red 8.1.5 NICE TA612: Neratinib for Add [Nerlynx] extended adjuvant treatment of hormone receptor-positive, HER2- positive early stage breast cancer after adjuvant trastuzumab 18/12/19 Sodium zirconium Red 9.2.1.1 NICE TA599: for treating Add cyclosilicate powder for hyperkalaemia oral suspension [Lokelma] 18/12/19 Cyclizine Green 4.6 RAG status updated. Amend tablet/injection Red Remains as green for oral, intramuscular or subcutaneous administration. Changed to red for intravenous administration. Due to safety concerns, intravenous use of cyclizine at UHS is restricted to short- term (i.e. single dose) only.
18/12/19 Oxetacaine & antacid oral Amber 12.3.1 Reclassified from ‘red’ to Amend suspension ‘amber’ as per DPC recommendations Dec 2019. Unlicensed product included in Drug Tariff specials list. For use in cancer care for oral mucositis and oesophageal lesions causing painful swallowing (see monograph here).
18/12/19 Ibrutinib tablets Red 8.1.5 Tablets introduced in various Amend [Imbruvica] strengths to replace capsules formulation (discontinued) Date Drug and formulation Colour BNF Comments Action status section
18/12/19 Cefazolin injection Red 5.1.2.1 For MSSA bacteraemia in Add patients with mild penicillin allergy who are not suitable for treatment with flucloxacillin. SPC and PIL available on MHRA website. 18/12/19 Fluticasone propionate Amber 12.2.1 For chronic rhinosinusitis Add nasal drops [Flixonase with nasal polyps as second Nasule Drops] line option if control with glucocorticoid nasal sprays is insufficient. DPC recommend indication and intended duration of use should be communicated to primary care. 18/12/19 Melatonin modified Amber 4.1.1 Slenyto formulation added Amend release tablets as an option in accordance [Circadin/Slenyto] with DPC recommendations Aug 2019.
Restricted use - CAMHS initiation/supervision only for use in children with sleep disorders in accordance with DPC Shared Care guidance (currently under review). Tablets may be crushed but this will result in loss of modified-release properties. Note: use of Circadin in this setting will be off label, but is established practice. Current patients established on this formulation may continue.
21/11/19 Safinamide tablets Amber 4.9.1 Status amended to Amber Amend [Xadago] as per Shared Care Guidelines for Parkinson’s. Black triangle status removed. 21/11/19 Guanfacine Prolonged Amber 4.4 Added to formulary as per Add release tablets [Intuniv] CAMHS Shared Care guidelines for ADHD. 21/11/19 Insulin degludec 100 Green 6.1.1.2 Switched from amber to Amend units per ml injection green as per DPC Jun 19. [Tresiba]
21/11/19 Lumacaftor and ivacaftor Red 3.7 Added as per NHS England Add Tablets/granules access agreement. Negative [Orkambi] NICE TA398 removed for clarity. Date Drug and formulation Colour BNF Comments Action status section
21/11/19 Tezacaftor and ivacaftor Red 3.7 Added as per NHS England Add [Symkevi] access agreement for CF patients. 21/11/19 Ivacaftor tablets Red 3.7 Added as per NHS England Amend [Kalydeco] access agreement for CF patients. 21/11/19 Tranexamic acid 5% Red 2.11 Unlicensed special added for Add mouthwash use in post oral surgery bleeding. 21/11/19 Isavuconazole capsules Red 5.2.1 Added to formulary as Add or injection [Cresemba] already in use and commissioned by NHSE. 21/11/19 Rivaroxaban tablets Green 2.8.2 NICEIncluded TA607 on :Bluteq. Rivaro xaban Amend [Xarelto] for preventing atherothrombotic events in people with coronary or peripheral artery disease 21/11/19 Pentosan polyfusate Red 7.4.3 NICE TA610: Pentosan Amend sodium capsules polysulfate sodium for treating bladder pain syndrome. 21/11/19 Lanadelumab 300mg Red 3.4.3 NICE TA606: Lanadelumab Add subcutaneous injection for preventing recurrent attacks of hereditary angioedema. 21/11/19 Levonorgestrel IUS Amber 7.3.2.3 Second entry for use in Add [Kyleena] obstetrics off-label for heavy menstrual bleeding where Mirena/Levosert devices are too large
21/11/19 Lubiprostone capsules NA 1.6.7 Removed from formulary as Remove [Amitiza] has been discontinued in UK 21/11/19 Pembrolizumab injection Red 8.1.5 NICE TA477 removed and Amend replaced by TA600.
23/10/19 Pembrolizumab inj Red 8.1.5 NICE TA600: for untreated Amend metastatic squamous non small-cell lung cancer (with carboplatin and paclitaxel). For use within the Cancer Drugs Fund. 23/10/19 Botulinum neurotoxin Red 1.2 NICE TA605: Xeomin Amend type A [Xeomin] (botulinum neurotoxin type A) for treating chronic sialorrhoea. Date Drug and formulation Colour BNF Comments Action status section
23/10/19 Bictegravir/emtricitabine/ Red 5.3.1 Treatment for HIV-1 in Add enofovir/alafenamide adults in line with criteria tablets [Biktarvy] stipulated in NHS England Clinical Commissioning Policy (170131P). Specialist use only. 23/10/19 Pitolisant tablets [Wakix] Red 4.1 For specialist sleep clinic use Add in patients aged ≥18 years, only when conventional stimulants have failed/not tolerated, and sodium oxybate is not suitable/not tolerated.
23/10/19 Flecainide oral solution Amber 2.3.2 Unlicensed special. Add 25mg in 5ml For use in children unable to swallow tablets.
23/10/19 Heparin Sodium Flush 50 Amber 2.8.1 Restricted use in primary Amend units in 5ml care. GPs to prescribe only for children for administration by specialist paediatric community nurses.
28/08/19 Bedaquiline tablets Red 5.1.9 For multidrug-resistant and Add [Sirturo] extensively drug-resistant tuberculosis in line with criteria stipulated in NHS England Clinical Commissioning Policy (170132P). Specialist use only. All patients must be registered on Blueteq. 28/08/19 Delamanid tablets Red 5.1.9 For multidrug-resistant and Add [Deltyba] extensively drug-resistant tuberculosis in line with criteria stipulated in NHS England Clinical Commissioning Policy (170132P). Specialist use only. All patients must be registered on Blueteq. Date Drug and formulation Colour BNF Comments Action status section
28/08/19 DEKAs/DEKAs Plus Amber 9.6.7 Vitamin and mineral Add vitamins supplements for use when liquid/capsules/chewable recommended by a tabs/softgels specialist in patients with cystic fibrosis For further info see website (link) 28/08/19 Paravit-CF vitamins Amber 9.6.7 Fat-soluble vitamin Add liquid/capsules supplements for use when recommended by specialist in patients with cystic fibrosis. For further info see website (link) 28/08/19 Clobetasone, Green 13.4 For short-term use only in Add oxytetracycline, nystatin accordance with product cream [Trimovate] licence. Not usually a first- line treatment. Note: remains non-formulary for off label use in chronic wound management 28/08/19 Nusinersen injection Red 10.2 NICE TA588: for treating Amend [Spinraza] spinal muscular atrophy
28/08/19 Blinatumomab injection Red 8.1.5 NICE TA589: for treating Amend acute lymphoblastic leukaemia in remission with minimal residual disease activity 28/08/19 Fluocinolone acetonide Red 11.4.1 NICE TA590: for treating Amend intravitreal implant recurrent non-infectious [Iluvien] uveitis 28/08/19 Letermovir tablets Red 5.3.2.2 NICE TA591: for preventing Add [Prevymis] cytomegalovirus disease after a stem cell transplant. 28/08/19 Cemiplimab injection Red 8.2.4 NICE TA592: for treating Add [Libtayo] metastatic or locally advanced cutaneous squamous cell carcinoma. 28/08/19 Ribociclib tablets [Kisqali] Red 8.1.5 NICE TA593: for treating Amend hormone receptor-positive, HER2-negative, advanced breast cancer. 28/08/19 Dacomitinib tablets Red 8.1.5 NICE TA595: for untreated Add [Vizimpro] EGFR mutation-positive non- small-cell lung cancer.
17/7/19 Triamcinolone with Green 13.04 Removed from formulary as Remove chlortetracycline discontinued Feb 2017. ointment (Aurecort) Date Drug and formulation Colour BNF Comments Action status section
17/7/19 Lenalidomide capsules Red 8.2.4 TA586: Lenalidomide plus Add (Revlimid) dexamethasone for multiple myeloma after 1 treatment with bortezomib TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
19/6/19 PARI O-PEP; Aerobika; Amber 3.12 For initiation by specialist Add Acapella Choice physiotherapist or oscillating positive respiratory clinician only. expiratory pressure For airways clearance in devices selected patients with chronic sputum-producing lung disease, e.g. cystic fibrosis, bronchiectasis, COPD. All follow up and monitoring of patients, and routine replacement of devices to be carried out in secondary care. Primary care prescribing on FP10 only when required for urgent supply of additional/replacement device (Drug Tariff listed approved appliances). PARI O-PEP 1st choice, Aerobika 2nd, Acapella 3rd. [Note: all other OPEP devices (e.g. Flutter, RC- Cornet, LungFlute) non- formulary – for use in exceptional circumstances 19/6/19 Mepivacaine 3% injection Red 15.2 only].For specialist use only in Add [Scandonest Plain] Solent Sexual Health Service. For selected patients as intra-cervical block to facilitate insertion of intra- uterine contraception (off- label use) in accordance with FSRH guidance. 19/6/19 Epimax Paraffin-free Green 13.2.1 Restricted - for use only in Add ointment patients intolerant to paraffin-containing products. Note: MHRA safety warnings re: fire risks also apply to paraffin-free emollients.
Note: MHRA safety warnings re:
fire risks also apply to paraffin-
free emollients.
Date Drug and formulation Colour BNF Comments Action status section
19/6/19 Diclofenac sodium 75mg Red 15.1.4.2 Restricted to paediatric Amend in 3ml inj theatres only, or for adults if ketorolac injection not available. Refer to product information or Medusa IV guide for instructions on administration. Must be diluted and buffered prior to administration by IV infusion. Not suitable for IV bolus. Use in children is off label. 19/6/19 Glycopyrronium - 1.2 May be continued in existing Remove 320micrograms/ml oral patients. solution [Sialanar] 1mg/5ml oral solution preferred for new patients.
19/6/19 Glycopyrronium Bromide Amber 1.2 For severe sialorrhoea in Add 1mg/5ml oral solution children and adolescents with chronic neurological disorders.
19/6/19 Rosuvastatin tabs Green 2.12 Reserved for use in patients Add requiring high intensity statin unable to tolerate/unsuitable for atorvastatin or high dose 19/6/19 Hyaluronic acid gel Red 7.5 Forsimvastatin localised use in the Amend uterus only, for prevention of adhesions. Use products registered as medical devices (i.e. CE marked) or medicines only, e.g. Hyalobarrier®; Hyaregen®; Materegen®.
19/6/19 Tafamidis caps Red 2.14 Specialist use only. NHS Add [Vyndaqel] England specialised commissioning for treatment of transthyretin amyloid cardiomyopathy in adults in Trusts providing specialised amyloidosis services. Available via MHRA EAMS application for eligible patients. Not routinely stocked at UHS. If required, liaise with lead divisional pharmacist. Date Drug and formulation Colour BNF Comments Action status section
19/6/19 Trientine caps/tabs Red 9.8.1 Specialist use only. For Add treatment of Wilson's disease in accordance with NHS England Clinical Commissioning Policy. Not routinely stocked at UHS. If required please liaise with divisional lead pharmacist. [N.B. Available as trientine dihydrochloride 300mg capsules and trientine tetrahydrochloride (Cuprior) 150mg tablets. NHS England confirm that both formulations will be commissioned] 19/6/19 Durvalumab inj [Imfinzi] Red 8.1.5 NICE TA578: for locally Add advanced unresecatble non- small-cell lung cancer after platinum-based chemoradiation 19/6/19 Ocrelizumab inj Red 8.2.4 NICE TA585: for treating Amend [Ocrevus] primary progressive multiple scerosis 19/6/19 Atezolizumab infusion Red 8.1.5 NICE TA584: for treating Amend metastatic non-squamous non-small-cell lung cancer (in combination)
19/6/19 Ertugliflozin tabs Green 6.1.2.3 NICE TA583: with metformin Amend and a DPP-4 inhibitor for treating type 2 diabetes 19/6/19 Inotersen inj [Tegsedi] Red 9.8.1 NICE HST9: for treating Add hereditary transthyretin amyloidosis 13/6/19 Burosumab inj [Crysvita] Red 9.8.1 NICE HST8: for treating X- Add linked hypophosphataemia in children and young people. UHS is a specialist centre.
22/5/19 Nivolumab inj Red 8.1.5 NICE TA581: for untreated Amend advanced renal cell carcinoma, with ipilimumab. Available through Cancer Drugs Fund, only if conditions in the managed access agreement are followed. Date Drug and formulation Colour BNF Comments Action status section
22/5/19 Abemaciclib tabs Red 8.1.5 NICE TA579: for HR+, Amend HER2- advanced breast cancer (with fulvestrant after endocrine therapy). Available through Cancer 22/5/19 Brentuximab vedotin inj Red 8.1.5 NICEDrugs TA577 Fund.: for CD-30+ Amend cutaneous T-cell lymphoma 22/5/19 Conestat alfa inj Red 3.4.3 For treatment of acute Add [Ruconest] severe attacks in hereditary angioedema due to C1 inhibitor deficiency/dysfunction in accordance with NHS England Specialised Clinical Commissioning policy only (Ref NHSCB/B09/P/b). 22/5/19 Mexiletine caps Red 10.2.2 For the treatment of Add [Namuscla] myotonia in patients with non-dystrophic myotonic disorders. Specialised commissioning. Remains amber for cardiology patients (unlicensed) – section 2.3.2
24/4/19 Pertuzumab inj Red 8.1.5 NICE TA569: for adjuvant Amend treatment of HER 2-positive early stage breast cancer 24/4/19 Brigatinib tabs Red 8.1.5 NICE TA571: for ALK- Add positive advanced non-small cell lung cancer after crizotinib 24/4/19 Ertugliflozin tabs Green 6.1.2.3 NICE TA572: for type 2 Add diabetes, as monotherapy or with metformin 24/4/19 Daratumumab infusion Red 8.1.5 NICE TA573: for previously Amend treated multiple myeloma, with bortezomib and dexamethasone (Cancer Drugs Fund) 24/4/19 Certolizumab pegol Red 13.5.3 NICE TA574: for moderate Amend to severe plaque psoriasis
24/4/19 Tildrakizumab inj Red 13.5.3 NICE TA575: for moderate Add [Ilumetri] to severe plaque psoriasis
24/4/19 Ciclosporin eye drops Amber 11.4.2 Ophthalmologist initiation Add [Verkazia] only. Prescribe by brand name (different licensed indication to Ikervis brand). Date Drug and formulation Colour BNF Comments Action status section
24/4/19 Lixisenatide inj 6.1.2.3 No longer recommended by Remove UHS diabetes team for new patients. May be continued in established patients. 24/4/19 Semaglutide inj Green 6.1.2.3 Add [Ozempic]
25/3/19 Safinamide tabs Red 4.9.1 Supported by DPC June Add 2018 – awaiting shared care guidance. Added to formulary as ‘red’ in interim. Restricted use for late-stage Parkinson’s Disease and motor fluctuations where treatment with rasagiline/selegiline and entacapone has failed/not tolerated.
20/3/19 Ulipristal tabs [Esmya] Red 6.7.2 Amended from amber to red Amend in view of MHRA safety update Aug 2018 20/3/19 Abemaciclib tabs Red 8.1.5 NICETA563: for previously Add [Verzenios] untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer 20/3/19 Encorafenib caps Red 8.1.5 NICE TA562: with Add [Braftovi] binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
20/3/19 Venetoclax tabs Red 8.1.5 NICE TA561: with rituximab Amend for previously treated CLL 20/3/19 Benralizumab inj Red 3.4.2 NICE TA565: for severe Add [Fasenra] eosinophilic asthma 20/3/19 Latanoprost with timolol Amber 11.6 Added ‘unit dose eye drops’ Amend eye drops/unit dose eye (Fixapost) as preservative- drops free option for combination prostaglandin analogue/beta-blocker (more cost effective than tafluprost/timolol or bimatoprost/timolol). Use restricted to patients allergic/intolerant of preservatives or high risk of developing allergy since generic (preservative- containing) latanoprost/timolol remain significantly lower cost. Date Drug and formulation Colour BNF Comments Action status section
20/3/19 Cobicistat tablets Red 5.3.1 Specialist only, in line with Add (Tybost); NHSE Clinical Cobicistat/elvitegravir/em Commissioning Policy tricitabine/tenofovir F03/P/b disoproxil fumarate tablets (Stribild); Cobicistat/darunavir/emtr icitabine/tenofovir alafenamide fumarate tablets (Symtuza)
27/2/19 Grass pollen allergen Red 3.4.2 Specialist allergy clinics only Add extract (Grazax®) inj
27/2/19 Lais® 1,000 AU sublingual Red 3.4.2 Unlicensed (available by Add tablets import). Specialist allergy clinics only, for use when licensed alternatives are not suitable
27/2/19 Progesterone Green 6.4.1.2 For oral administration as Add (micronised) HRT 100mg (Utrogestan®) capsules 27/2/19 Lidocaine medicated See 4.7.3 Restricted use. Amend plaster 5% comme Green for use in patients nts who have been treated in line with NICE CG173: Neuropathic pain, but are still experiencing pain associated with previous herpes zoster infection (post-herpetic neuralgia) (licensed indication). Amber for chronic neuropathic pain/focal neuralgia ['off label' use] in exceptional circumstances only (e.g. other treatment options have failed or cannot be used due to co- morbidities) in a co- operation arrangement with chronic pain or cancer care/palliative care specialist teams as per DPC Chronic Pain Prescribing Guidelines or Wessex Palliative Care Guidelines. Red for use in rib fracture pain (section 15.02).
Date Drug and formulation Colour BNF Comments Action status section
27/2/19 Diclofenac oral Red 10.1.1 Unlicensed special. Add suspension 50mg in 5ml Restricted use - short term use for postoperative analgesia in children. Second line to ibuprofen and only when licensed options are not suitable.
30/1/19 Regorafenib tabs Red 8.1.5 TA555: for previously Amend [Stivarga] treated advanced hepatocellular carcinoma 30/1/19 Nivolumab infusion Red 8.1.5 TA558: for adjuvant Amend [Opdivo] treatment of completely resected melanoma with lymph node involvement or metastatic disease 30/1/19 Lenvatinib caps Red 8.1.5 TA551: for untreated Amend [Lenvima] advanced hepatocellular carcinoma
30/1/19 Liposomal daunorubicin- Red 8.1.5 TA552: for untreated acute Add cytarabine myeloid leukaemia infusion[Vyxeos]
30/1/19 Pembrolizumab inj Red 8.1.5 TA553: for adjuvant Amend [Keytruda] treatment of resected melanoma with high risk of recurrence (available through Cancer Drugs Fund)
TA557: for untreated, metastatic, non-squamous non-small-cell lung cancer, with pemetrexed and platinum chemotherapy (available through Cancer Drugs Fund)
Date Drug and formulation Colour BNF Comments Action status section
30/1/19 Hydrocortisone granules Amber 6.3.1 Restricted for use only when Add in capsules for opening standard tablets are not [Alkindi] suitable or practical, e.g. infants/young children on doses <5mg. UHS will only routinely stock lower strengths, i.e. 0.5mg, 1mg and 2mg. Patients on doses ≥5mg should be switched to standard tablets, which can be divided using a tablet cutter. Unlicensed in patients <18 years. Discuss options for adult patients unable to swallow tablets with pharmacist.
30/1/19 Clobetasone butyrate 13.4 No longer supported by DPC Remove 0.05% with 11.12.18. oxytetracycline 3% and nystatin cream [Trimovate] 30/1/19 Adalimumab biosimilar Red 1.5.3; Biosimilars now available at Add injections [Imraldi, 10.1.3; UHS for use in all indications Amgevita] 11.4; (except paediatric uveitis). 13.5.3 3/1/19 Bumetanide Green 2.2.2 Removed injection Amend tablet/liquid/injection formulation as product discontinued (not ordered at UHS since 2012)
21/12/18 Tofacitinib tabs Red 1.5.3 TA547: Previously treated Add moderately to severely active ulcerative colitis 21/12/18 Acetic acid spray [Ear Blue 12.1.1 Ad(adults)ded for use in primary Add Calm] care for otitis externa 21/12/18 Dexamethasone/framycet Green 12.1.1 Changed from amber to Amend in/gramicidin ear drops green [Sofradex] (remains amber for ocular use) 21/12/18 Dexamethasone/neomyci Green 12.1.1 Changed from amber to Amend n/acetic acid spray green [Otomize] Date Drug and formulation Colour BNF Comments Action status section
21/12/18 Empagliflozin Green 6.1.2.3 Remove statement “first line Amend SGLT-2 inhibitor for patients with established cardiovascular disease”. Trial data now supports CV safety and possible benefits for all 3 licensed drugs in this class 21/12/18 Ranolazine prolonged- Amber 2.6.3 Specialist recommendation Add release tabs [Ranexa] only. Third-line option for stable angina where other anti-anginals are contraindicated/not tolerated/ due to hypotensive and/or bradycardic effects and revascularisation options not available 21/12/18 Pregabalin caps Green 4.7.3; Changed from amber to Amend 4.8.1 green for neuropathic pain and anxiety (remains amber for epilepsy)
21/12/18 Gemtuzumab ozogamicin Red 8.1.5 TA545: Acute myeloid Add infusion leukaemia (CD-33 positive, untreated)
21/12/18 Levofloxacin nebuliser Red 5.1.2 For use according to NHS Add solution [Quinsair] (special England commissioning ised policy for chronic commis Pseudomonas lung infection sioning in cystic fibrosis (adults) )
24/10/18 Bezafibrate MR tab Amber 2.12 Additional use off-label for Amend treatment of primary biliary cholangitis 24/10/18 Tocilizumab inj Red 10.1.3 Additional use for treatment Amend of toxicities associated with CAR-T cell therapy 24/10/18 Moviprep Red 1.6.5 First choice bowel prep Add
24/10/18 Cabozantinib tab Red 8.1.5 TA 542: Advanced renal cell Amend carcinoma 24/10/18 Tofacitinib tab Red 10.1.3 TA 543: Active psoriatic Amend arthritis
24/10/18 Dabrafenib Red 8.1.5 TA 544: Adjuvant in BRAF Amend cap/Trametinib tab V600 +ve melanoma
26/09/18 Tacrolimus granules Red/A 8.2.2 Formulation added for use in Add mber paediatrics. Red for transplant indications, amber for all other indications Date Drug and formulation Colour BNF Comments Action status section
26/09/18 Lutetium (177Lu) Red 8.1.5 TA539: Unresectable Add oxodoteotride infusion metastatic neuroendocrine tumours 26/09/18 Pembrolizumab infusion Red 8.2.4 TA540: Relapsed or Add refractory classical Hodgkin 26/09/18 Inotuzumab ozogamicin Red 8.1.5 TA5lymphoma41: Relapsed/refractory Add infusion B-cell acute lymphoblastic leukaemia
29/08/18 Aprepitant liquid Red 4.6 Prevention of N+V with Add highly and moderately emetogenic chemotherapy in children 6months-12 years. 29/08/18 Rifampicin/isoniazid/ Red 5.1.9 To be used in place of Add pyrazinamide/ethambutol separate constituents. 50 tablets patients to initiate therapy [Rimstar/Voractiv] but not all will continue on quadruple therapy. 29/08/18 Ciprofloxacin and Red 12.1 For acute otitis Add dexamethasone ear drops externa/media where [Cilodex] aminoglycoside should not be used. Licensed 29/08/18 Ulipristal acetate tablets Amber 6.7.2 Removedpreparation. due to safety Add [Esmya] concerns. Added in line with MHRA restrictions. 29/08/18 Levonorgestrel IUS Green 7.3.2.3 Alternative IUS. Add [Levosert/Kyleena]
29/08/18 Levonorgestrel IUS 7.3.2.3 Replaced by Kyleena Remove [Jaydess]
29/08/18 Golimumab inj Red 1.5.3 Additional indication for use Add in Crohn’s disease. 29/08/18 Glycopyronnium bromide Green 1.2 For severe sialorrhoea in Add liquid [Sialanar] children and adolescents with chronic neurological disorders. 29/08/18 Trehalose/sodium Green 11.8.1 For the treatment of dry Add hyaluronate eye drops eyes, in line with guidelines. [Thealoz-duo] 29/08/18 Riluzole liquid Amber 4.9.3 For patients who have Add difficulty crushing tablets 29/08/18 Budesonide MR tablets Amber 1.5.2 Specifically formulated for Add [Cortiment] UC 29/08/18 Piracetam tablets Amber 4.8.1 In line with NICE guidance. Add 29/08/18 Stiripentol capsules Amber 4.8.1 To add for use in adults in Amend line with NICE guidance. 29/08/18 Prednisolone rectal foam Amber 1.5.2 For use in paediatrics only Add
Date Drug and formulation Colour BNF Comments Action status section
29/08/18 Oxycodone injection Amber 4.7.2 Amber for use in palliative Amend care 29/08/18 Fluticasone/Umeclidinium Green 3.2 Triple combination DPI for Add /Vilanterol inhaler COPD [Trelegy] 29/08/18 Enoxaparin injection Amber 2.8.1 Change from red to amber Amend for extended 29/08/18 Pembrolizumab infusion Red 8.1.5 TA531:thromboprophylaxis PD-L1+ve NSCLC Add
29/08/18 Ocrelizumab infusion Red 8.2.4 TA533:Relapsing-remitting Add MS 29/08/18 Dupilumab injection Red 13.5.3 TA534: Moderate to severe Add atopic dermatitis 29/08/18 Levatinib capsules & Red 8.1.5 TA535: Thyroid cancer Add Sorafenib tablets 29/08/18 Alectinib capsules Red 8.1.5 TA536: ALK +ve NSCLC Add
29/08/18 Ixekizumab injection Red 13.5.3 TA537: Psoriatic arthritis Add
29/08/18 Dinutuximab beta Red 8.1.5 TA538: For neuroblastoma Add infusion 29/08/18 Emicizumab inj Red 8.1.5 Policy 170067/P: Add Prophylaxis in people with congenital haemophilia A with factor VIII inhibitors. 29/08/18 Idebenone capsules Red 11.8.1 For DMD as part of EAMS. Add
18/07/18 Fentanyl nasal spray Amber 4.7.2 For use in palliative care, Add [Pecfent] endorsed by DPC. Prescribe by brand. 18/07/18 Fentanyl sublingual tablets Amber 4.7.2 For use in palliative care, Add [Abstral] endorsed by DPC. Prescribe by brand. 18/07/18 Celecoxib capsules Green 10.1.1 Endorsed by DPC. Add
18/07/18 Parecoxib injection Red 10.1.1 For use in palliative care by Add CSCI as per palliative care formulary. Endorsed by DPC. 18/07/18 Ondansetron tablets Green 4.6 Change from amber to Amend green endorsed by DPC.
18/07/18 Intranasal diamorphine Red 4.7.2 For severe acute pain in Add paediatric patients in ED.
18/07/18 Ticagrelor orodispersible TBC 2.9 As per NICE TA236. An Add tablets option for patients unable to swallow clopidogrel. Date Drug and formulation Colour BNF Comments Action status section
18/07/18 Epimax ointment Green 13.2.1 Cheaper preparation to Add replace Epaderm ointment.
18/07/18 Lacosamide injection Red 4.8.1 For NBM patients. Add
18/07/18 Guselkumab inj Red 13.5.3 TA 521: For plaque psoriasis Add
18/07/18 Pembrolizumab inj Red 8.1.5 TA 522: For metastatic Amend urothelial carcinoma when cisplatin unsuitable 18/07/18 Midostaurin capsules Red 8.1.5 TA 523: For FLT-3 +ve Add myeloid leukaemia
18/07/18 Brentuximab vedotin inj Red 8.1.5 TA 524: For CD-30 +ve Amend Hodgkin lymphoma
18/07/18 Atezolizumab infusion Red 8.1.5 TA 525: For metastatic Amend urothelial carcinoma after platinum chemotherapy 18/07/18 Arsenic trioxide infusion Red 8.1.5 TA 526: For promyelocytic Add leukaemia
18/07/18 Beta-interferon injection Red 8.2.4 TA 527: For multiple Amend sclerosis
18/07/18 Glatiramer acetate Red 8.2.4 TA 527: For multiple Amend sclerosis
18/07/18 Niraparib capsules Red 8.1.5 TA 528: For fallopian tube Add and peritoneal cancer
18/07/18 Crizotinib capsules Red 8.1.5 TA 529: For NSCLC Amend
18/07/18 Nivolumab infusion Red 8.1.5 TA 530: For metastatic Amend urothelial cancer
25.06.18 Pegvisomant inj Red 6.8.1 As per commissioning Add criteria
25.06.18 Sildenafil liquid Red 2.5.1 For pulmonary hypertension Add in line with specialised commissioning criteria 25.06.18 Eculizumab inj Red 9.1.3 NICE HST1 Add Date Drug and formulation Colour BNF Comments Action status section
25.06.18 Zafirlukast tabs Amber 3.3.2 Discontinued by Remove manufacturers
29/05/18 Flunarizine tab/caps Non- 4.7.4.2 Not evaluated by DPC. Add (as non- formula Unlicensed in the UK. Not formulary) ry recommended for prescribing locally. 23/05/18 Timolol 0.1% unit dose Amber 11.6 Cheaper alternative Add eye gel preservative-free preparation for glaucoma 23/05/18 Pembrolizumab inf Red 8.1.5 TA 519: For locally advanced Add or metastatic urothelial carcinoma 23/05/18 Atezolizumab inf Red 8.1.5 TA 520: For locally advanced Add or metastatic non-small-cell lung cancer
25/04/18 Mydriasert (tropicamide Red 6.7.2 For pre-operative mydriasis. Add and phenylephrine ophthalmic insert)
25/04/18 Pentosan Polysulfate Red 7.4.3 Recommended for use Add sodium caps (Unlicensed) locally, but not for use in primary care. 25/04/18 Cabozantinib caps Red 8.1.5 TA 516: For medullary Amend thyroid cancer 25/04/18 Avelumab inj Red 8.1.5 TA 517: For metastatic Add Merkel cell carcinoma 25/04/18 Tocilizumab inj Red 10.1.3 TA 518: For giant cell Amend ateritis 25/04/18 Levofloxacin tab Red 5.1.2 In line with trust guidelines Add and for prophylaxis in newly diagnosed myeloma patients
28/03/18 Ulipristal tab - 6.7.2 Removed due to safety Remove warnings 28/03/18 Daclizumab inj - 8.2.2 Removed due to safety Remove warnings 28/03/18 Acetylcysteine Amber 3.7 Added in place of unlicensed Add effervescent tab formulation, for existing IPF 28/03/18 Sofosbuvir-velpatasvir- Red 5.3.3.2 NICEpatients TA already507 – For on chronic Add voxilaprevir tabs hepatitistreatment C in adults Date Drug and formulation Colour BNF Comments Action status section
28/03/18 Pertuzumab inj Red 8.1.5 NICE TA 509 – In Add combination with trastuzumab and doxetaxel for breast cancer 28/03/18 Daratumumab inj Red 8.1.5 NICE TA 510 – For relapsed Add or refractory multiple myeloma 28/03/18 Brodalumab inj Red 13.5.3 NICE TA 511 – Moderate to Add severe plaque psoriasis
28/03/18 Tivozanib cap Red 8.1.5 NICE TA 512 – Advanced Add renal cell carcinoma 28/03/18 Obinutuzumab inj Red 8.2.3 NICE TA 513 – Advanced Add follicular lymphoma
26.02.18 Ivermectin tablets Red 13.10.4 Restricted use - on Add microbiology advice only 26.02.18 High sodium powders Red 9.2.1.2 Nutrition team only Add (“St. Mark’s solution”) (For scabies - unlicensed) (Added to formulary again following notice from manufacturers to discontinue Glucodrate sachets) 22.02.18 Ibrutinib cap Red 8.1.5 TA502: For Amend relapsed/refractory mantle cell lymphoma 22.02.18 Ceritinib cap Red 8.1.5 TA500: For ALK positive non Amend small cell lung cancer 22.02.18 Glecaprevir with Red 5.3.3.2 TA499: For chronic hepatitis Add pibrentasvir cap [Maviret] C
22.02.18 Everolimus tab [Afinitor] Red 8.1.5 TA498: with lenvatinib for Amend advanced renal cell 22.02.18 Lenvatinib cap [Kisplyx] Red 8.1.5 TA498:carcinoma with everolimus for Add advanced renal cell 22.02.18 Golimumab inj Red 10.1.3 TA497:carcinoma For non-radiographic Amend axial spondyloarthritis 22.02.18 Ixazomib cap Red 8.1.5 TA505: For Add relapsed/refractory multiple myeloma 22.02.18 Pirfenidone cap Red 3.11 TA504: For idiopathic Amend pulmonary fibrosis (replaces TA282) Date Drug and formulation Colour BNF Comments Action status section
22.02.18 Viteyes 2 Formula Amber 9.6.7 Removed from formulary as Remove caps/softgels recommended by DPC Feb 2018. No new patients and GPs/ophthalmologists to deprescribe in current patients. Patients wishing to continue may purchase OTC. 22.02.18 Plasma-Lyte 148; N/A 9.2.2.1 Restricted - for use in Add Plasma-Lyte 148 with Southampton Children’s Glucose 5% w/v Hospital as alternative to intravenous infusion compound sodium lactate (Hartmann’s) and as standard fluid of choice.
22.02.18 Humulin I (isophane Green 6.1.1.2 Not a brand of choice at UHS Add insulin) inj but several patients admitted on it therefore added to formulary.
22.02.18 Infliximab biosimilar inj Red 1.5.3 For use in gastroenterology Add [Flixabi] patients at UHS.
Prescribe by brand name.
22.02.18 Topiramate tab/sprinkle Green 4.7.4.2 Change from amber to Amend cap green for migraine prophylaxis
22.02.18 Dupilumab inj Red 13.5.3 (RemainsConsultant ambe dermatologistr for epilepsy Add –only. BNF section 4.8.1) For eligible adult patients with moderate to severe atopic dermatitis poorly controlled with topical agents and intolerant of or unsuitable for systemic immunosupressants. 22.02.18 Alendronic acid Green 6.6.2 Restricted use. Not a first Add effervescent – once line option. weekly tab For use only in patients unable to swallow conventional bisphosphonate tablets, and unwilling/unsuitable for treatment with parenteral options.
(See DPC Update Feb 2018)
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist Add 17.01.18 Atezolizumab inj Red 8.1.5 TA492:commission For untreatedcriteria locally Add advanced or metastatic urothelial carcinoma in adults Date Drug and formulation Colour BNF Comments Action status section
17.01.18 Cladribine tab Red 8.2.4 TA493: For relapsing- Amend remitting MS 17.01.18 Palbociclib cap Red 8.1.5 TA495:For locally advanced Add or metastatic breast cancer 17.01.18 Ribociclib tab Red 8.1.5 TA496: For locally advanced Add or metastatic breast cancer 17.01.18 Miconazole vaginal Green 7.2.2 Discontinued Remove capsule 17.01.18 Miconazole vaginal cream Green 7.2.2 To replace capsules Add
17.01.18 Aprotinin infusion Red 2.11 Restricted to use by Cardio- Add thoracic anaesthetist only
13.12.17 Mercaptamine eye drops Red 9.8.1 As per NHSE specialist Add commission criteria
13.12.17 Mercaptamine tablets Red 9.8.1 As per NHSE specialist Add commission criteria 13.12.17 Regorafenib tab Red 8.1.5 TA488 – For GI stromal Add tumours 13.12.17 Nivolumab inj Red 8.1.5 TA 490 – For SCC of the Amend head and neck 13.12.17 Ibrutinib cap Red 8.1.5 TA 491 – For Waldenstrom’s Amend macroglobulinaemia 13.12.17 Thiotepa inj Red 8.1.5 For treatment of CNS diffuse Add large B cell lymphoma 13.12.17 Colesevelam tablets Amber 2.12 Second line to colestyramine Add for bile acid malabsorption 13.12.17 Eslicarbazepine tab Amber 4.8.1 Third line to carbamazepine Add and oxcarbazepine 13.12.17 Beclometasone, Amber 3.2 Add formoterol and glycopyrronium inhaler [Trimbow] 13.12.17 Insulin degludec and Amber 6.1.2.3 Change from red to amber Amend liraglutide injection [Xultophy] 13.12.17 Omega 3 capsule Red 2.12 Removed
29.11.17 Dexmedetomidine inj Red 15.1.4.4 Restricted for use for Add sedation to NeuroICU consultant only 29.11.17 Renestart powder 9.4 Replace Kindergen powder Add
29.11.17 Ketamine 100mg/ml IM Red 2.11 Unlicensed product. Use Add injection restricted to senior ED/anaesthetic registrars and consultants Date Drug and formulation Colour BNF Comments Action status section
29.11.17 Brimonidine/timolol eye Amber 11.6 DPC approved 10/10/2017 Add drops
29.11.17 Brinzolamide/timolol eye Amber 11.6 DPC approved 10/10/2017 Add drops 29.11.17 Bimatoprost/timolol eye Amber 11.6 DPC approved 10/10/2017 Add drops 29.11.17 Cladribine tab Red 8.1.3 For use in MS in line with Add specialised commissioning 29.11.17 Nivolumab inj Red 8.1.5 TA483/4circular – For previously Add treated squamous and non- squamous NSCLC
29.11.17 Sarilumab inj Red 10.1.3 TA 485 – For moderate to Add severe rheumatoid arthritis 29.11.17 Aflibercept intravitreal Red 11.8.2 TA 486 – For choroidal Add injection neovascularisation in adults 29.11.17 Venetoclax tab Red 8.1.5 TA 487 – For chronic Add lymphocytic leukaemia
01.11.17 Roflumilast tab Amber 3.3.2 As per DPC 10/2017 Amend
01.11.17 Enoxaparin inj Various 2.8.1 Note added to prescribe by Amend brand name as biosimilar Inhixa now available and in use 01.11.17 Glycopyrrolate 0.05% in Amber Amend aqueous solution
01.11.17 Opicapone caps Amber As per DPC 10/2017 Add 01.11.17 Optho-Lique eye drops Green 11.8.1 Add
01.11.17 Ropinirole MR tab Amber 4.9.1 Add
01.11.17 Ceftazidime/ Avibactam Red 5.1.2.1 Add inj 01.11.17 Autologus chondrocyte Red TA 477 – For treating Add implantation articular cartilage defects of the knee 01.11.17 Brentuximab inj Red 8.1.5 TA 478 – For relapsed or Amend refractory systemic anaplastic large cell lymphoma in adults 01.11.17 Reslizumab inj Red 3.4.2 TA 479 – For severe Add eosinophillic asthma inadequately controlled in adults 01.11.17 Tofacitinib tab Red 10.1.3 TA 480 – For moderate to Add severe rheumatoid arthritis Date Drug and formulation Colour BNF Comments Action status section
01.11.17 Basiliximab inj, Red 8.2 TA 481/2 – Amend tacrolimus, Immunosuppressive therapy mycophenolate mofetil for kidney transplant in adults/children
01.11.17 Nusinersen inj Red SCC 1777 Add
11.10.17 Neomycin eye oint Green 11.3.1 Removed from formulary as Remove formulation discontinued
27.09.17 Dimethyl fumarate tab Red 8.2.4 TA 475 Amend
27.09.17 Eluxadoline tab Amber 1.2 TA 471 Add
27.09.17 Oralvac compact Red 3.4.2 Specialist allergy clinic only. Add oromucosal solution Second line therapy if Pollinex not suitable 27.09.17 Pseudoephedrine tab Red 3.10 For the emergency Add treatment of priapism 27.09.17 Sorafenib tab Red 8.1.5 TA 474 Add 27.09.17 Paclitaxel albumin inj Red 8.1.5 TA 476 Add 27.09.17 Cetuximab inj Red 8.1.5 TA 473 Amend 27.09.17 Obinutuzumab inj Red 8.2.3 TA 472 Amend
12.09.17 Ambrisentan tab Red 2.5.1 Only for patients already Add commenced on therapy by commissioned centre for pulmonary hypertension 12.09.17 Bosentan tab Red 2.5.1 Only for patients already Add commenced on therapy by commissioned centre for pulmonary hypertension 12.09.17 Anti-human T- Red For use as per Add Lymphocyte commissioning criteria set immunoglobulin by NHS England 12.09.17 Cidofovir inf Red 5.3.2.1 For use as per Add commissioning criteria set 12.09.17 Co-careldopa 20mg/ml Red 4.9.1 Forby NHS use asEngland per Add Gel cassette commissioning criteria set by NHS England 12.09.17 Deferasirox disp tab Red 9.1.3 For use as per Add commissioning criteria set 12.09.17 Deferiprone tab Red 9.1.3 Forby NHS use asEngland per Add commissioning criteria set 12.09.17 Everolimus (Votubia) tab Red 8.1.5 Forby NHS use asEngland per Add commissioning criteria set by NHS England 12.09.17 Icatibant inj Red 3.4.3 For use as per Add commissioning criteria set by NHS England Date Drug and formulation Colour BNF Comments Action status section
12.09.17 Plerixafor inj Red 9.1.7 For use as per Add commissioning criteria set by NHS England 12.09.17 Sodium oxybate liq Red 4.1.1 For use in children as per Add commissioning criteria set by NHS England 08.09.17 Oilatum/Zerolatum Oilatu 13.2.1.1 Added Zerolatum as blue. Amend fragrance free bath m = additive green, 08.09.17 Dermol 500 lotion ZerolatGreen 13.2.1 Additional information Amend um = “Note: this contains an blue antimicrobial. Not recommended for long-term use.” 08.09.17 Epaderm/Hydromol/Zero Epader 13.2.1 Amended Hydromol from Amend derm ointment m/Hydr blue to green, added omol = Zeroderm as blue. green, Zerode rm = 08.09.17 Aqueous cream /ZeroAQS Aqueoublue) 13.2.1 Added ZeroAQS as blue. Amend cream s Amended further crm=gr information to indicate een, ZeroAQS as potential ZeroAQ alternative (SLS-free). 08.09.17 Doublebase/Isomol/Zerod DoubleS = 13.2.1 Added Isomol and Amend ouble gel baseblue = Zerodouble as blue. green, Isomol/ Zeroba 08.09.17 Diprobase/Epimax/Zerob Diprobse = 13.2.1 Added Epimax and Zerobase Amend ase cream/ointment aseblue = as blue. green, Epimax / 08.09.17 Tadalafil 10mg and 20mg ZerobaGreen 7.4.5 ‘Further information’ Amend tab se = wording has been amended blue to clarify once-daily dosing not recommended, and entry now specifies 10mg and 20mg strengths to 08.09.17 Morphine sulfate tab/MR Green 4.7.2 Suppository now unlicensed Amend reflect this (2.5mg and 5mg cap/liq/MR (licensed has been to be considered as non- sachet/inj/suppository discontinued, only available formulary). as special). Added TA number 273.
31.08.17 Magnesium Amber 9.5.1.3 Added brand name – new, Amend glycerophosphate 2mmol licensed formulation (caps cap/4 mmol chewable tab remain unlicensed) [Neomag] Date Drug and formulation Colour BNF Comments Action status section
31.08.17 Liraglutide inj Green 6.1.2.3 Amended wording around Amend maximum doses, as NICE no longer specifies. Removed TA203 as this has been updated and replaced by NG28.
30.08.17 Budesonide rectal foam Amber 1.5.2 Replacing prednisolone Add enema rectal foam in light of price increase 30.08.17 Prednisolone rectal foam Amber 1.5.2 Replaced by budesonide Remove enema 30.08.17 Buspirone tab Amber 4.1.2 Change from red to amber Amend approved by DPC 30.08.17 Retigabine tab Amber 4.8.1 Product discontinued Remove
30.08.17 Levemir (insulin detemir) Green 6.1.1.2 Change from amber to Amend inj green approved by DPC 30.08.17 Insulin Aspart [Fiasp] inj Amber 6.1.1.1 Recommended by DPC. For Add specialist recommendation. 30.08.17 Glucodrate powder Amber 9.2.1.2 Replacing St Mark’s solution. Add Approved by DPC 30.08.17 High sodium powders (“St Red 9.2.1.2 Replaced by Glucodrate Remove Mark’s Solution”)
30.08.17 Ketocal liquid N/A 9.4 Replacing ketocal powder Add
30.08.17 Anamix feeds N/A 9.4 Add
30.08.17 Diphtheria, tetanus, 5 Green 14.4 Replaced by hexavalent Remove component acellular vaccine on routine schedule pertussis, inactivated polio 30.08.17 Diphtheria,vaccine and tetanus, haemop hilus Green 14.4 As per routine immunisation Add influenzaepertussis, polio,type b vaccine schedule from Autumn 2017 Haemophilus influenzae type b (Hib) and hepatitis B [Infanrix hexa]
30.08.17 Cabozantinib tab Red 8.1.5 TA 463 – For advanced renal Add cell carcinoma in adults after VEGF-targeted therapy
30.08.17 Olaratumab inj Red 8.1.5 TA 465 – For use within the Add CDF as an option for soft tissue sarcoma 30.08.17 Baricitinib tab Red 10.1.3 TA 466 – An option for Add moderate to severe RA
Date Drug and formulation Colour BNF Comments Action status section
26.07.17 Lucozade Red 6.1.6 No longer suitable for oral Remove glucose tolerance test due to reduced glucose content 26.07.17 Strontium ranelate Green 6.6.2 Discontinued. Remove granules 26.07.17 Donepezil orodispersible Green 4.11 For patients with swallowing Add tabs difficulties 26.07.17 Oxycodone capsules Green 4.7.2 For patients unable to Add tolerate liquid. Not for ward 26.07.17 Albendazole tab Red 5.5 stock Add
26.07.17 Hydrocortisone, neomycin Amber 12.1.1 Product previously Add and polymyxin B ear discontinued added back drops [Otosporin] onto market
26.07.17 Meningococcal Group A, Green 14.4 Added as per splenectomy Add C, W135 and Y conjugate guidelines previously vaccine (Menveo) approved by drugs committee June 2015 26.07.17 Vancomycin inj/cap Red/a 5.1.7 Injection only to be used Amend mber orally where capsules are unable to be given
26.07.17 Adalimumab, etanercept Red 13.5.3 TA 455 Amend and ustekinumab inj
26.07.17 Ustekinumab inj Red 1.5.3 TA 456 Amend
26.07.17 Pembrolizumab inj Red 8.1.5 TA 447 Amend 26.07.17 Etelcalcetide inj Red 9.5.1.2 TA 448 Add
26.07.17 Everolimus tab and Red 8.1.5 TA 449 Amend sunitib cap 26.07.17 Blinatumomab inj Red 8.1.5 TA 450 Add
26.07.17 Ponatinib tab Red 8.1.5 TA 451 Add
26.07.17 Carfilzomib inj Red 8.1.5 TA 457 Add 26.07.17 Trastuzumab emtansine Red 8.1.5 TA 458 Add inj 26.07.17 Collagenase clostridium Red 10.3.1 TA 459 Amend histolyticum [Xiapex] 26.07.17 Adalimumab Red 10.1.3/ TA 460 Amend inj/Dexamethasone 11.4.1 implant 26.07.17 Roflumilast tab Red 3.3.2 TA 461 Add
Date Drug and formulation Colour BNF Comments Action status section
28.06.17 Diphenylcyclopropenone Red 13.12 Dermatology only. Add in acetone 0.00001-6.0% Unlicensed ; as per BAD w/v specials list, previously agreed at DPC 28.06.17 Salicyclic acid in Amber 13.12 Unlicensed ; as per BAD Add emulsifying ointment specials list, previously 2%,5%,10%, 20% agreed at DPC
28.06.17 Dithranol in Lassar’s paste Red 13.5.2 Unlicensed ; as per BAD Add 0.1% - 15% w/w specials list, previously agreed at DPC 28.06.17 Salicyclic acid 5%/ Amber 13.4 Unlicensed ; as per BAD Add propylene glycol 47.5% in specials list, previously clobetasol propionate agreed at DPC 0.05% (Dermovate) 28.06.17 Propylenecream glycol 20% w/w Amber 13.2.2 Unlicensed ; as per BAD Add in aqueous cream specials list, previously agreed at DPC
28.06.17 Glycopyrrolate 2% w/w in Red 13.12 Dermatology only. Add cetomacrogol cream Unlicensed ; as per BAD specials list, previously agreed at DPC 28.06.17 Glycopyrrolate 0.05% in Red 13.12 Dermatology only. Add aqueous solution Unlicensed ; as per BAD specials list, previously agreed at DPC 28.06.17 Reflectant (Dundee) Amber 13.8.1 Unlicensed ; as per BAD Add sunscreens - coffee, coral specials list, previously pink, beige agreed at DPC 28.06.17 Eosin solution 2% Red 13.12 Unlicensed ; as per BAD Add specials list, previously agreed at DPC 28.06.17 Ibandronic acid tab Amber 6.6.2 Specialist initiation under Amend shared care agreement ‘off- label’ for patients assessed as being at increased risk of recurrence of breast cancer.
28.06.17 Aviptadil 25 Amber 7.4.5 Specialist initiation in Add microgram/phentolamine urology clinic. mesilate 2mg Second line after alprostadil. intracavernosal inj [Invicorp] 28.06.17 Desmopressin tab (except Green/ 6.5.2 Noqdirna - Not Amend Noqdirna)/nasal Amber recommended by DPC. spray/intranasal Safety concerns re: use solution/inj without specialist support.
28.06.17 Fortini compact multifibre N/A 9.4 Add Date Drug and formulation Colour BNF Comments Action status section
28.06.17 Neocate Junior N/A 9.4 Add
28.06.17 Similac Alimentum N/A 9.4 Formula milk for CMPA. On Add infant guidelines, cheaper alternative to Nutramigen 1 and 2. 28.06.17 Nutramigen 1 and 2 N/A 9.4 Replaced by Similac Remove Alimentum 28.06.17 Isotretinoin gel None 13.6.1 Discontinued Remove 28.06.17 Certolizumab pegol inj Red 10.1.3 TA 445 Amend
28.06.17 Secukinumab inj Red 10.1.3 TA 445 Amend 28.06.17 Brentuximab inj Red 8.1.5 TA 446 Add
28.06.17 Levosimendan inj Red 2.1 Specialist use only Add
28.06.17 Obeticholic acid tab Amber 1.9.1 NICE TA 443 Add
24.05.17 Dexamethasone soluble Green 6.3.2 Add tabs 24.05.17 Quattro solution Red 11.9 Contact lens solutions Remove removed from formulary. No longer sourced through pharmacy and not to be prescribed by GPs 24.05.17 Opti-free express Red 11.9 24.05.17 Miraflow Red 11.9 Add 24.05.17 Amiclair protein remover Red 11.9 24.05.17 Saline spray Red 11.9 24.05.17 Boston advance Red 11.9 24.05.17 Netupitant/Palonosetron Red 4.6 24.05.17 Cocaine[Akynzeo] 5% capsules nasal spray Red 15.2 Add
24.05.17 Fondaparinux inj Red 2.8.1 New indication for superficial Amend thrombophlebitis 24.05.17 Dalbavancin inj Red 5.1.7 Restricted to microbiology Add recommendation 24.05.17 Triamcinolone/gramicidin/ Red 12.1.1 For ENT use. Unlicensed Add neomycin/nystatin [Triadcortyl] ointment
24.05.17 Daclizumab inj Red 8.2.4 NICE TA 441 Add
24.05.17 Ixekizumab inj Red 13.5.3 NICE TA 442 Add
Date Drug and formulation Colour BNF Comments Action status section
19.04.17 Adapalene 0.1%, benzoyl Green 13.6.1 For treatment of acne Add peroxide 2.5% gel vulgaris. Positive [Epiduo] recommendation by DPC.
19.04.17 Pilocarpine eye gel Amber 11.6 Discontinued 2012. Not used Remove since then as alternative eye drops are available 19.04.17 Dexmedetomidine inj Red 15.1.4.4 Additional use in paediatric Amend laryngotracheobronchoscopy
19.04.17 Diclofenac inj Red 15.1.4.2 Restricted to use in Add paediatric theatres 19.04.17 Humulin R insulin 500 Red 6.1.1 Unlicensed. All prescribing Add units/ml and monitoring to be carried out by specialists 19.04.17 Cetuximab inj Red 8.1.5 TA 439 Amend 19.04.17 Panitumumab inj Red 8.1.5 TA 439 Add
30.03.17 Benzoyl peroxide 4% Green 13.6.1 Now discontinued Remove and cream [Brevoxyl] replace with item below
30.03.17 Benzoyl peroxide gel Green 13.6.1 To replace Brevoxyl (see Add above) 21.03.17 Tiotropium inhalation Green 3.1.2 Amended wording to include Amend powder caps/solution for “Prescribe by brand name” inhalation as new brand now available (Braltus®) which delivers tiotropium via a different device. 21.03.17 Minocycline tabs Amber 5.1.3 & Removed from Formulary. Remove 13.6.2 SafetyPrescribers concerns are advised mean no to longermaintain recommended patients on currentfor use inbrand, acne. but may opt to start new patients on Braltus Anybrand other (lower use cost will). be as non[Note:-formulary. both brands deliver 10micrograms tiotropium 15.03.17 Adapalene gel/cream Green 13.6.2 Added cream formulation. Amend per inhalation] Useful for patients with dry, sensitive skin and same cost as gel. Date Drug and formulation Colour BNF Comments Action status section
14.03.17 Viteyes 2 Formula Amber 9.6.7 & Amended wording to clarify Amend caps/softgels or OTC 11.8.2 restrictions on use, as follows: “Restricted use – Specialist (secondary care ophthalmologist) recommendation only, for patients who have advanced AMD (category 4) in one eye only. Patients who do not meet criteria may opt to purchase OTC.”
01.03.17 Apremilast tab Red 13.5.3 NICE TA 433 Add Added softgels as new formulation option (slightly 01.03.17 Everolimus tab Red 8.1.5 NICE TA 432 Add cheaper than caps and same 01.03.17 Hydroquinone 5%, Red 13.12 Unformula)licensed. Add hydrocortisone 1%, tretinoin [Pigmanorm] cream
01.03.17 Tafluprost/ Timolol Amber 11.6 Add [Taptiqom] preservative free eye drops
01.03.17 Rasagiline tablets Amber 4.9.1 Add
01.03.17 Ivermectin cream Green 13.6.3 First line option for the Add treatment of Papulopustular rosacea
31.01.17 Ticagrelor tab Green 2.9 NICE TA 420 Amend
31.01.17 Everolimus tab Red 8.1.5 NICE TA 421 Add 31.01.17 Crizotinib cap Red 8.1.5 NICE TA 422 Amend 31.01.17 Eribulin inj Red 8.1.5 NICE TA 423 Add 31.01.17 Pertuzumab inf Red 8.1.5 NICE TA 424 Add 31.01.17 Dasatinib, nilotinib and Red 8.1.5 NICE TA 425/426 Amend 31.01.17 Pomalidomideimatinib cap Red 8.1.5 NICE TA 427 Add
31.01.17 Pembrolizumab inf Red 8.1.5 NICE TA 428 Amend
31.01.17 Ibrutinib cap Red 8.1.5 NICE TA 429 Add
31.01.17 Sofosbuvir/velpatasvir Red 5.3.3.2 NICE TA 430 Add 31.01.17 Mepolizumabtabs inj Red 3.4.2 NICE TA 431 Add
31.01.17 Mannitol inhalation Red 3.7 For diagnostic testing for Add powder [Osmohale] bronchial hyperresponsiveness Date Drug and formulation Colour BNF Comments Action status section
31.01.17 Mesalazine [Salofalk] Amber 1.5.1 1st line preparation for Add granules patients with distal disease. Second line treatment for pan-colitis
11.01.201 Tacrolimus MR cap Red/A 8.2.2 Red for renal transplant, Add 7 mber amber for all other indications. For continuation in established patients only.
Added to Formulary in line with other local organisations (e.g. West Hants CCG, Portsmouth, Dorset)
14.12.201 Apremilast tab Red 13.5.3 NICE TA 419 Add 6 14.12.201 Dapagliflozin tab Green 6.1.2.3 NICE TA 418 Amend 6 14.12.201 Nivolumab inj Red 8.1.5 NICE TA 417 Amend 6 14.12.201 Ataluren granules Red 10.2 NICE HST (Highly Add 6 Specialised Technologies 14.12.201 Ciclesonide inhaler Amber 3.2 Specialistguidance) recommendation3 Add 6 as a steroid sparing agent at step 4/5 of the BTS guidelines 14.12.201 Lecicarbon A Amber 1.6 Specialist recommendation Add 6 suppositories as per chronic constipation guidelines 14.12.201 Pancrex V granules Amber 1.9.4 For use in patients who Add 6 require administration of pancreatin via enteral feeding tubes.
14.12.201 Sodium hyaluronate Green 11.8.1 Add 6 (Clinitas Multi) 0.4% eye drops
14.12.201 Stiripentol Amber 4.8.1 For use in paediatric Add 6 capsules/powder patients with severe myoclonic epilepsy
14.12.201 Alfacalcidol liq/caps Amber 9.6.4 Amend to amber/add caps Amend 6 14.12.201 Calcitriol caps Amber 9.6.4 Amend to amber Amend 6 Date Drug and formulation Colour BNF Comments Action status section
14.12.201 Toujeo U300 (Insulin Amber 6.1.1.2 Specialist initiation Add 6 glargine) 300units/ml inj
14.12.201 Tresiba U200 (Insulin Amber 6.1.1.2 Specialist initiation Add 6 degludec) 200units/ml inj
14.12.201 Humalog U200 (Insulin Amber 6.1.1.1 Specialist initiation Add 6 lispro) 200units/ml
14.12.201 Emtricitabine/tenofovir Red 5.3.1 GUM and Child health Add 6 tab specialist only. As per local commissioning arrangements 14.12.201 Estradiol patches Green 6.4.1.1 Amend from blue to green. Amend 6 Remove branding
23.11.201 Azithromycin inj Red 5.1.5 Remove words second line Add 6 macrolide – follow guideline 23.11.201 Elbasvir-grazoprevir tab Red 5.3.3.2 NICE TA 413 Add 6 23.11.201 Certolizumab-pegol inj Red 10.1.3 NICE TA 415 Amend 6 23.11.201 Osimertinib tab Red 8.1.5 NICE TA 416 Add 6
26.10.201 Degarelix inj Amber 8.3.4.2 NICE TA404 Amend 6 Specialist initiation only for 26.10.201 Crizotinib cap Red 8.1.5 NICEselected TA406 patients in Add 6 accordance with NICE TA guidance. 26.10.201 Secukinumab inj Red 10.1.3 NICE TA407 Amend (add TA 6 (Removed previous number) 26.10.201 Pegaspargase inj Red 8.1.5 NICErestriction TA408 for use only in Amend (add TA 6 emergency situations as a number) single dose) 26.10.201 Aflibercept inj Red 11.8.2 NICE TA409 Amend (add TA 6 number) 26.10.201 Talimogene Red 8.1.5 NICE TA410 Add 6 laherparepvec inj Specialist use only in 26.10.201 Radium-223 dichloride inj Red 8.1 NICEaccordance TA412 with special Amend (add TA 6 Aprecautions radiopharmaceutical for handling for and number) usedisposal and administration(refer to SPC only bysection authorised 6.6). persons. To be prepared in pharmacy at UHS. Date Drug and formulation Colour BNF Comments Action status section
26.10.201 Sodium hyaluronate Red N/A Urology specialist use only Add 6 1.6% and sodium at UHS for patients with chondroitin sulphate 2% insufficient response or intravesical instillation intolerant to other therapies, [iAluRil] including Hyacyst (refer to UHS Painful Bladder Syndrome Protocol) 11.10.201 Azelastine & fluticasone Green 12.2.1 Third line therapy for allergic Add 6 propionate nasal spray rhinitis where response to [Dymista] treatment with other therapies, including a combination of oral antihistamines and intranasal corticosteroids, was inadequate or not tolerated 11.10.201 Ulipristal acetate tab Amber 6.4.1.2 Specialist recommendation Amend (added 6 [Esmya] as an option for pre- new indication) operative treatment of uterine fibroids or for intermittent treatment of uterine fibroids where first line therapies are inappropriate
11.10.201 Midazolam inj Green 15.1.4.1 Green for use in palliative Add 6 care only (remains red for all other indications)
11.10.201 Amiodarone tab Amber 2.3.2 Amended to amber as Amend 6 requested by DPC (safety (changed from reasons) green to amber) 11.10.201 Calcium lactate and Amber 9.5.1.1 Specialist recommendation Add 6 calcium gluconate oral for paediatric patients only. liquid 0.51mmol/ml Licensed as a nutritional [Alliance Calcium Syrup] supplement. 11.10.201 Omeprazole oral solution Amber Not Specialist(Prescribe recommendationby brand name in Add 6 listed onlyprimary for paediatriccare) patients (unlicensed product)
11.10.201 Ganciclovir 0.15% eye Green 11.3.3 Second line option when Add 6 gel aciclovir eye oint is unavailable 11.10.201 Ferric maltol cap Amber 9.1.1.1 Gastoenterology specialist Amend 6 [Feraccru] initiation only for patients with IBD unable to tolerate other oral iron preparations 11.10.201 Fosfomycin oral sachets Green 5.1.7 Prescribe in line with local Amend 6 [Monuril] guidance/in response to (changed to antimicrobial sensitivities green from amber) Date Drug and formulation Colour BNF Comments Action status section
28.09.201 Azithromycin 1.5% eye Red 11.3.1 Add 6 drops
28.09.201 Trifluridine-tipiracil tab Red 8.1.3 NICE TA 405 Add 6 28.09.201 Pemetrexed inj Red 8.1.3 NICE TA 402 Add 6 28.09.201 Bosutinib tab Red 8.1.5 NICE TA 401 Add 6 28.09.201 Amphotericin Green 12.3.2 Discontinued Remove 6 suspension/lozenges 28.09.201 Hydrocortisone, Amber 12.1.1 Product discontinued May Remove 6 neomycin and polymyxin 2014 B ear drops [Otosporin]
28.09.201 Co-codamol 30/500 Green 4.7.1 For patients with swallowing Add 6 effervescent tabs difficulties/enteral feeding tubes 28.09.201 Carbocisteine oral Amber 3.7 Add 6 sachets 07.09.201 Midazolam inj Amber 15.1.4.1 Amber for use in palliative Add 6 care only
17.08.201 Ferric maltol cap Red 9.1.1.1 Gastroenterology only Add 6
17.08.201 Evolocumab inj Red 2.12 NICE TA 394 Add 6 17.08.201 Alirocumab inj Red 2.12 NICE TA 393 Add 6
17.08.201 Paliperidone palmitate Red 4.2.2 3 monthly preparation for Add 6 prolonged release patients already stabilised suspension for injection on the one monthly depot. [Trevicta]
17.08.201 Clobazam suspension Green 4.8.1 For paediatric patients or Add 6 [Tapclob] those with swallowing difficulties 17.08.201 Progesterone vaginal Red 6.4.1.2 For emergency supply to Add 6 capsules [Utrogestan] patients treated by the fertility unit only.
17.08.201 Progesterone 8% vaginal Red 6.4.1.2 Replaced by capsules above Remove 6 gel Date Drug and formulation Colour BNF Comments Action status section
17.08.201 Nivolumab infusion Red 8.1.5 NICE TA 400 Add 6
17.08.201 Trametinib tab Red 8.1.5 NICE TA 396 Add 6 17.08.201 Ceritinib cap Red 8.1.5 NICE TA 395 Add 6 17.08.201 Belimumab infusion Red 10.1.3 NICE TA 397 Add 6 17.08.201 Transvasin cream Red 13 For use in the respiratory Add 6 centre, prior to capillary 17.08.201 Cetraben cream Green 13.2.1 blood gas sampling Add 6
17.08.201 Calcipotriol and Green 13.5.2 Add 6 betamethasone cutaneous foam [Enstilar]
17.08.201 Adalimumab inj Red 13.5.3 NICE TA 392 Add 6
17.08.201 Tacrolimus inj Red 8.2.2 For patients already Add 6 receiving therapy who 17.08.201 Macitentan tab Red 2.5.1 Forbecome patients nil by managed mouth under Add 6 a shared care agreement with the Royal Brompton hospital only
19.07.201 Phenothrin 0.5% liquid Blue 13.10.4 Discontinued Remove 6 [Full Marks] (Now re-formulated using alternative active ingredient)
22.6.2016 Fostair 100/6 DPI Green 3.2 Add
22.6.2016 Brivaracetam tab/liq/inj Amber Not For specialist initiation. Use Add listed restricted to selected 22.6.2016 Methotrexate tab/inj (NB Amber 10.1.3 & Specialistpatients (e.g. initiation inadequate (unless Amend Once weekly) 13.5.3 GPseizure indicates control a preferenceor where to initiateother antiepileptic therapy). drugs are Seecontraindicated, DPC Shared notCare Guideline.tolerated or inappropriate).
22.6.2016 Cisatracurium inj Red 15.1.5 Add
22.6.2016 Atracurium inj Red 15.1.5 Remove
22.6.2016 Cabazitaxel inj Red 8.1.5 NICE TA391 Add Date Drug and formulation Colour BNF Comments Action status section
22.6.2016 Canagliflozin, Green 6.1.2.3 NICE TA390 Amend dapagliflozin and empagliflozin tablets
22.6.2016 Adrenaline (epinephrine) Green 3.4.3 Remove the words “for self- Amend autoinjector [Jext 150 administration” microgram or 300 microgram; EpiPen 0.3mg or Jr 0.15mg; Emerade 150 microgram, 300 microgram or 500 microgram]
22.6.2016 Axitinib tablets Red 8.1.5 NICE TA333 Add
22.6.2016 5-aminolevulinic acid Red Not Use supported by DPC Add hydrochloride (Ameluz) listed 11.6.2013 gel 22.6.2016 Mirabegron MR tab Green 7.4.2 NICE TA 290 – Listed as Amend green and amber on current formulary, status should be green 22.6.2016 Leuprorelin 3.75mg inj Amber 6.7.2 & Organisations can now Amend 8.3.4.2 choose which brand to prescribe. Remove current branding
18.5.2016 3,4-diaminopyridine tab Red 10.2.1 Amifampridine base is a Amended, synonym for this medicine. amifampridine base added to 3,4- diaminopyridin e 18.5.2016 Prosource TF liquid 45ml N/A Appendi Approved by Drugs Added sachet (Nutrinovo) x 1 (List Committee for UHS patients 2) receiving enteral feed who are not meeting protein requirements with standard enteral feeds. 18.5.2016 Peptamen Junior Advance N/A Appendi Approved by drugs Added x 1 (List committee for paediatric 2) patients at UHS receiving enteral feed who are not meeting energy requirements within the volume allowance of a 1kcal enteral feed Date Drug and formulation Colour BNF Comments Action status section
18.5.2016 Sacubitril-valsartan Amber Not NICE TA388. Local Added, with TA tablets currently agreement from CCGs for 1 number listed month’s supply to be initiated in secondary care and then continued in primary care. 18.5.2016 Abiraterone tablets Red 8.3.4.2 NICE TA387 Amended, added TA number 18.5.2016 Topotecan, pegylated Red 8.1 NICE TA389, replaces Amended, liposomal doxorubicin TA91/222. added TA hydrochloride, paclitaxel, number and trabectedin and removed TA gemcitabine number
18.5.2016 Edrophonium inj Red 10.2.1 Discontinued. Removed Unlicensed product last used 25.11.14.
18.5.2016 Diclofenac inj 37.5 mg/ml Green 15.1.4.2 Discontinued. Removed
20.4.16 Ruxolitinib tab Red 8.2.4 TA386 Added, with TA number 20.4.16 Etanercept biosimilar inj Red 10.1.3 & Specify brand Added [Benepali] 13.5.3
Biosimilar. Recently approved for use at UHS. 20.4.16 Beclometasone and Green 3.2 For asthma only Added formoterol MDI [Fostair 200/6]
20.4.2016 Nortriptyline tab Green 4.3.1 & Reviewed by MEC and DPC. Removed 4.7.3 No longer recommended in NICE Guidance or local guidance for neuropathic pain. High cost versus other options. Use alternative agents according to indication.
23.3.2016 Ezetimibe tab Green 2.12 TA385 Amended, Remove TA132 added TA (TA385 replaces TA132) number and removed TA number Date Drug and formulation Colour BNF Comments Action status section
23.3.2016 Nivolumab inj [Opdivo] Red 8.2.4 TA384 Added, with TA number
23.3.2016 Infliximab inj Red 1.5.3, TA383. Amended, [Remicade]; Infliximab 10.1.3 & Remove TA143. added TA biosimilar inj [Inflectra, 13.5.3 (TA383 replaces TA143) number Remsima]
23.3.2016 Golimumab inj [Simponi] Red 1.5.3 & Added brand name. Amended, 10.1.3 TA383. added TA number 23.3.2016 Certolizumab pegol inj Red 10.1.4 Added brand name. Amended, [Cimzia] TA383. added TA number 23.3.2016 Etanercept inj [Enbrel] Red 10.1.3 & Added brand name to Amended, 13.5.3 formulary entry to avoid any added TA confusion as biosimilar now number and also available. removed TA TA383. number Remove TA143. (TA383 replaces TA143) 23.3.2016 Adalimumab inj [Humira] Red 1.5.3, Added brand name. Amended, 10.1.3 & TA383. added TA 13.5.3 Remove TA143. number and (TA383 replaces TA143) removed TA number 23.3.2016 Radium-223 dichloride Red 8.1 Specialist use only. TA376. Added, with TA injection number 23.3.2016 Stanozolol tab Red 6.7.2 Specialist immunology use Added only.
For long-term prophylaxis of hereditary angioedema attacks [Unlicensed drug and off-label indication]. Second-line option. Only for patients unable to tolerate danazol (note: long-term supply problems mean unlikely to be able to obtain stocks of this drug) Date Drug and formulation Colour BNF Comments Action status section
23.3.2016 Oxandrolone tab Red 6.7.2 Specialist immunology use Amended only.
For long-term prophylaxis of hereditary angioedema attacks [Unlicensed drug and off-label indication]. Third-line option. Only if stanozolol not available (long-term supply problem).
23.3.2016 Iron (III) isomaltoside Red 9.1.1.2 First-line IV iron preparation Added 1000 injection [Monofer] at UHS. Ferinject remains on formulary for patients not suitable for Monofer (e.g. <18 years)
14.3.2016 Tadalafil tab Green 7.4.5 Added wording “Not Amended recommended locally for treatment of benign prostatic hyperplasia.”
14.3.2016 Pixantrone injection Red 8.1.2 TA306 Added, with TA number Was due to be added April 2014, but not actioned.
14.3.2016 Aripiprazole prolonged- Red 4.2.2 For use in secondary Added release injection [Abilify psychiatric care. Maintena] Was due to be added April 2014, but not actioned.
17.2.2016 Esomeprazole inj Red 1.3.5 In UHS: Child Health only Added
17.2.2016 Golimumab inj Red 10.1.3 [PTA375antoprazole remains as Amended, preferred IV PPI for adult added TA 17.2.2016 Certolizumab inj Red 10.1.3 patients]TA375 Amended,number added TA number
17.2.2016 Etanercept inj Red 10.1.3 TA375 Amended, added TA number 17.2.2016 Adalimumab inj Red 10.1.3 TA375 Amended, added TA number 17.2.2016 Abatacept inj Red 10.1.3 TA375 Amended, added TA number Date Drug and formulation Colour BNF Comments Action status section
17.2.2016 Tocilizumab inj Red 10.1.3 TA375 Amended, added TA number 17.2.2016 Infliximab inj Red 10.1.3 TA375 Amended, [Remicade]; Infliximab added TA biosimilar inj [Inflectra, number Remsima] 17.2.2016 Enzalutamide cap Red 8.3.4.2 TA377 Amended, added TA number 17.2.2016 Nintedanib cap Red 8.1.5 TA379 Amended, added TA number 17.2.2016 Olaparib cap Red 8.1.5 TA381 Added, with TA number 17.2.2016 Bortezomib inj Red 8.1.5 TA380 Amended, added TA number 17.2.2016 Panobinostat tab Red 8.1.5 TA380 Added, with TA number 17.2.2016 Vortioxetine tab Amber 4.3.4 TA367 Added, with TA number 17.2.2016 Idarucizumab inj Red 2.8.3 When rapid reversal of Added [Praxbind] dabigatran is required for emergency surgery/urgent procedures or in life- threatening or uncontrolled bleeding. On Consultant Haematologist advice only (refer to UHS guideline).
17.2.2016 Degarelix 120mg inj Red 8.3.4.2 Consultant urologist use Added only as a SINGLE DOSE (240mg) in patients with naive prostate cancer who present with emergencies such as: Spinal cord compression. Severe uraemia due to malignant ureteric obstruction. Impending long bone pathological fracture.
Not for long-term treatment. 20.1.2016 Erlotinib tab Red 8.1.5 TA374 Amended, added TA number Date Drug and formulation Colour BNF Comments Action status section
20.1.2016 Bortezomib inj Red 8.1.5 TA370 Amended, added TA number
20.1.2016 Abatacept inj Red 10.1.3 TA373 Amended, added TA number 20.1.2016 Adalimumab inj Red 10.1.3 TA373 Amended, added TA number 20.1.2016 Etanercept inj Red 10.1.3 TA373 Amended, added TA number 20.1.2016 Tocilizumab inj Red 10.1.3 TA373 Amended, added TA number 20.1.2016 Ingenol gel [Picato] Green 13.8.1 Status change from amber Amended to green
30.12.201 Dasabuvir tab Red 5.3.3.2 NICE TA365 Amended, 16.12.2015 Ciclosporin eye drops Amber 11.8.1 NICESpecialist TA369 use only Amended,added TA 5 Specialist addednumber NICE TA initiation/recommendation number. 16.12.201 Dulaglutide inj Green 6.1.2.3 Removed wording “Not a Amended only Changed colour 5 first line option, but may be from red to considered for patients with amber. compliance problems or
needle phobia, or for
patients with kidney impairment (see prescribing information and local guidelines)“ 16.12.201 Empagliflozin tab Green 6.1.2.3 Added wording “First line Amended 5 SGLTAs recommended-2 inhibitor for by patients withDiabetes established Sub Committee of cardiovascularDPC – restrictions disease” removed as now priced more Ascompetitively recommended versus by other DiaGLPbetes-1 agonists. Sub Committee of DPC – recently published evidence to support positive outcomes in this patient group. 16.12.201 Denosumab inj Green 6.6.2 NICE TA204 Amended 5 Now green for prevention of Changed colour fractures in patients with from amber to osteoporosis. green
Remains red for cancer- related indications Date Drug and formulation Colour BNF Comments Action status section
16.12.201 Brinzolamide and Amber 11.6 Added 5 brimonidine eye drops [Simbrinza] 16.12.201 Daclatasvir tab Red 5.3.3.2 NICE TA364 Amended, 5 Specialist use only added TA number 16.12.201 Sofosbuvir and ledipasvir Red 5.3.3.2 NICE TA363 Amended, 5 tab [Harvoni] Specialist use only added TA number 16.12.201 Ombitasvir and Red 5.3.3.2 NICE TA365 Amended, 5 paritaprevir and ritonavir Specialist use only added TA tab [Viekiraz] number 16.12.201 Pembrolizumab inj Red 8.2.4 NICE TA366 Amended, 5 Oncology only added new TA number
16.12.201 Idelalisib tab Red 8.1.5 NICE TA359 Added 5 Oncology only
16.12.201 Tolvaptan tab Red 6.5.2 NICE TA358 Added 5 Specialist use only
18.11.201 Efavirenz tab/cap/liq Red 5.3.1 Liquid deleted as Amended 18.11.2015 Ingenol gel [Picato] Amber 13.8.1 N.B.discontinued both strengths by Added 5 (15manufacturers.0mcg/g and 500mcg/g) areRemoved approved. text “The oral solution is an alternative to 18.11.201 Granisetron patch Red 4.6 tabletsSpecialist in patientsuse only withas per Added 5 [Sancuso] nasogastriclicensed indications. tubes or 18.11.201 Erythromycin 2% and Green 13.6.1 (Isotrexinchildren” gel) Added 5 0.05% gel 18.11.201 Clindamycin 1% and Green 13.6.1 (Treclin gel) Added 5 tretinoin 0.025% gel 18.11.201 Magnesium aspartate Green 9.5.1.3 Licensed magnesium Added 5 dihydrate powder for oral supplement. solution Consider in preference to unlicensed preparations.
09.11.201 Phytomenadione cap Amber 9.6.6 Removed wording Amended 5 [Neokay] ‘unlicensed’ as now licensed as a POM. 02.11.201 Aclidinium DPI [Eklira Green 3.1.2 Added brand name Amended 5 Genuair]
02.11.201 Salbutamol MDI/breath- Green 3.1.1.1 Added Easyhaler as an Amended 5 actuated MDI/DPI (e.g. option as included in new Accuhaler/Easyhaler)/neb COPD Guidelines. /inj Date Drug and formulation Colour BNF Comments Action status section
02.11.201 Formoterol MDI [Atimos Green 3.1.1.1 Added Turbohaler as an Amended 5 Modulite]/Formoterol DPI option as included in new (e.g. COPD Guidelines. Easyhaler/Turbohaler)
02.11.201 Umeclidinium DPI Green 3.1.2 Included as an option in new Added 5 [Incruse Ellipta] COPD Guidelines.
02.11.201 Indacaterol inhalation Green 3.1.1.1 Included as an option in new Added 5 powder caps [Onbrez COPD Guidelines. Breezhaler]
02.11.201 Aclidinium and formoterol Green 3.1.4 Included as an option in new Added 5 DPI [Duaklir Genuair] COPD Guidelines.
02.11.201 Umeclidinium and Green 3.1.4 Included as an option in new Added 5 vilanterol DPI [Anoro COPD Guidelines. Ellipta] 02.11.201 Glycopyrronium and Green 3.1.4 Included as an option in new Added 5 indacaterol powder caps COPD Guidelines. [Ultibro Breezhaler]
02.11.201 Budesonide and Green 3.2 Added Duoresp Spiromax as Amended 5 formoterol DPI an option as included in new [Symbicort Turbohaler, COPD Guidelines. Duoresp Spiromax]
02.11.201 Olodaterol solution for Green 3.1.1.1 Included as an option in new Added 5 inhalation [Striverdi COPD Guidelines. Respimat]
02.11.201 Tiotropium and olodaterol Green 3.1.4 Included as an option in new Added 5 solution for inhalation COPD Guidelines. [Spiolto Respimat]
02.11.201 Pembrolizumab inj Red 8.2.4 NICE TA357 Added, with TA 5 Oncology only number
07.10.201 Sodium chloride 0.18% N/A 9.2.2 Not available Removed 5 and glucose 10% 500ml bags 07.10.201 Paediatric renal vitamins Amber Unlicens Discontinued by Removed 5 tab ed manufacturers
07.10.201 Hetastarch and N/A 9.2.2 Discontinued by Removed 5 Pentastarch (various manufacturers strengths) Date Drug and formulation Colour BNF Comments Action status section
07.10.201 Dinoprostone pessary Red 7.1.1 ‘Off label’ use at UHS for Added 5 [Propess] outpatient induction of labour (as per guideline/procedure) 07.10.201 Glatiramer acetate Red 8.2.4 Added wording ‘Specialist Amended 5 20mg/ml, 40mg/ml inj use only for multiple sclerosis’ (added strengths as both 07.10.201 Peginterferon beta-1a inj Red 8.4.2 nowSpecialist approved) use only for Added 5 multiple sclerosis (commissioned by NHS England)
07.10.201 Vedolizumab inj Red 1.5.3 NICE TA352 Amended, 5 Removed phrase ‘For added new TA ulcerative colitis’ (now also number recommended by NICE for Crohns Disease)
07.10.201 Edoxaban tab Green 2.8.2 NICE TA354/355 Added, with TA 5 numbers
07.10.201 Lidocaine plaster Red 15.2 ‘Off label’ use at UHS for Added 5 management of traumatic 07.10.201 Isotretinoin gel [Isotrex] Green 13.6.1 Replacementrib fractures (referfor tretinoin to Added 5 gelprotocol) .
07.10.201 Tretinoin gel [Retin A] Green 13.6.1 Discontinued by Removed 5 manufacturers
07.10.201 Ciclosporin eye drops/eye Red Amended wording to reflect Amended 5 ointment that only the eye ointment is unlicensed (eye drops now 07.10.201 Clindamycin cap/liq/inj Green 5.1.6 licensed)Caps and Liquid were Amended. 5 (Cap/li previously red. Discussed Changed colour q) with DPC Chair and from red to Red Microbiology - agreed green (inj) suitable for green status. Note: Liquid is unlicensed.
Remains red for pneumocystis pneumonia 07.10.201 Abasaglar (insulin Green 6.1.1.2 Some(section dose 5.4.8) adjustment may Added 5 glargine 100 Units/ml be needed if switching from biosimilar) inj other brands of insulin glargine (e.g. Lantus)
(First choice brand of insulin glargine for new patients) Date Drug and formulation Colour BNF Comments Action status section
09.09.201 Midodrine tab Green 6.1.5 Removed word “unlicensed” Amended 5 as a licensed preparation is now available (Bramox). Removed wording “for postural hypotension”. Prescribers should use SPC for guidance.
02.09.201 Nalmefene tab Amber 4.10.1 NICE TA325 Added, with TA 5 Only in conjunction with number continuous psychosocial support.
02.09.201 Sodium hyaluronate Green 11.8.1 e.g. Hylo-Tear, Hylo-Forte Amended. 5 0.1% and 0.2% eye (Brand name not specified in Changed colour drops (preservative-free) main entry to allow from amber to organisations to choose green preferred option) Included in Dry Eye Guidelines for Primary Care (pending) GP can initiate if required.
02.09.201 Carmellose sodium 0.5% Green 11.8.1 Included in Dry Eye Amended. 5 and 1% eye drops Guidelines for Primary Care Changed colour (preservative-free) (pending) from amber to GP can initiate if required. green Removed brand name ‘Celluvisc’ as several other brands now available. 02.09.201 Polyvinyl alcohol 1.4% Green 11.8.1 e.g. SnoTears, Liquifilm Amended. 5 eye drops and unit dose Tears Changed colour eye drops (preservative- (Brand name not specified in from amber to free) main entry to allow green organisations to choose preferred option) Included in Dry Eye Guidelines for Primary Care (pending) GP can initiate if required. 02.09.201 Carbomer 0.2% Green 11.8.1 e.g. Clinitas Gel Amended. 5 ophthalmic gel (Brand name not specified in Changed colour main entry to allow from amber to organisations to choose green preferred option) Included in Dry Eye Guidelines for Primary Care (pending) GP can initiate if required. Date Drug and formulation Colour BNF Comments Action status section
02.09.201 Hypromellose 0.3% Green 11.8.1 Included in Dry Eye Amended. 5 preservative-free eye Guidelines for Primary Care Changed colour drops (pending) from amber to GP can initiate if required. green Removed ‘Unlicensed’ as now available as a licensed medical device.
02.09.201 Tears Naturale eye drops Amber 11.8.1 No longer required. Removed 5 Not included in Dry Eye Guidelines for Primary Care (pending)
02.09.201 VitA-POS (retinol Green 11.8.1 Included in Dry Eye Added 5 palmitate, liquid paraffin, Guidelines for Primary Care wool fat, white soft (pending) paraffin) eye ointment Preservative-free formulation. 02.09.201 Propylene glycol & Green 11.8.1 Included in Dry Eye Added 5 polyethylene glycol unit Guidelines for Primary Care dose eye drops (pending) (preservative-free) Preservative-free alternative [Systane] to Systane Balance.
02.09.201 Propylene glycol eye Green 11.8.1 Included in Dry Eye Added 5 drops [Systane Balance] Guidelines for Primary Care (pending) 02.09.201 Dexamethasone Red 11.4.1 NICE TA349 Amended, 5 intravitreal implant added TA number 02.09.201 Aflibercept intravitreal inj Red 11.8.2 NICE TA367. Amended, 5 Removed wording “Also for added TA treatment of diabetic number macular oedema” as not needed now that approved by NICE.
02.09.201 Rifaximin tab [Targaxan] Red 5.1.7 Specialist use only as per Added 5 UHS guideline ‘Off-label’ use, third line antibiotic treatment for small bowel (short intestine) bacterial overgrowth
02.09.201 Hexaminolevulinate Red 7.4.4 UHS: Urology specialist use Added 5 intravesical instillation only in selected patients (e.g. high risk of multiple or flat tumours) 02.09.201 Secukinumab inj Red 13.5.3 NICE TA350 Added, with TA 5 number
02.09.201 Naloxegol tab Amber 1.6 NICE TA345 Added, with TA 5 number Date Drug and formulation Colour BNF Comments Action status section
02.09.201 Nintedanib cap Red 8.1.5 Specialist use only. Added, with TA 5 NICE TA347. number 02.09.201 Meningococcal Group B Green 14.4 Added 5 Vaccine 02.09.201 Nortriptyline tab Green 4.7.3 ‘Off-label’ use. Added 5 A second-line choice at step 2 of neuropathic pain ladder.
02.09.201 Nortriptyline tab Green 4.3.1 Not(Relatively a first linehigh option cost in Amended 5 primary care therefore Changed colour (Discussedamitriptyline at remains UHS Drugs first from red to Committeeline) and Chair’s green Action taken for DPC. No need for specialist-only (red) status, although relatively high cost in primary care therefore amitriptyline remains first line) 02.09.201 Ferrous sulfate tab Green 9.1.1.1 Second line oral iron Added 5 preparation
(re-added to formulary as this preparation appears to continue to be widely used in primary and secondary care) 02.09.201 Ferrous fumarate tab Green 9.1.1.1 Added phrase “First line oral Amended 5 iron preparation”
02.09.201 Aqueous cream Green 13.2.1 Removed phrase “first line” Amended 5 as Dermatology specialists no longer recommend
30.07.15 Co-beneldopa Amber 4.9.1 Added Amended (levodopa/benserazide) “levodopa/benserazide” for cap/disp tab/MR cap clarity. [Madopar] 30.07.15 Co-careldopa Amber 4.9.1 Moved brand name Amended (levodopa/carbidopa) “[Sinemet]” from main entry tab/MR tab to further info section, as other brands and generic versions now available. Added “levodopa/carbidopa” for clarity. Date Drug and formulation Colour BNF Comments Action status section
30.07.15 Co-careldopa Amber 4.9.1 Moved brand name Amended (levodopa/carbidopa) “[Stalevo]” from main entry with entacapone tab to further info section as other brands now available. Added “levodopa/carbidopa” for clarity.
23.07.15 Colecalciferol (vitamin Green 9.6.4 Added “vitamin D3” for Amended D3) cap/tab/liq clarification. Added tablet and liquid formulations. Added further information: “Products that are UK licensed medicines should be prescribed and supplied wherever possible.”
23.07.15 Carmellose sodium 0.5% Green 11.8.1 Amended wording from “If Amended eye drops [Optive] patient is allergic to commonly used preservatives” to “Contains a gentle preservative so may be an option if patient is allergic to commonly-used preservatives”
23.07.15 Humalog (insulin lispro) Amber 6.1.1.2 Added strength (100 Amended 100units/ml inj Units/ml) as new, high strength formulation now also available (has same brand name)
23.07.15 Tresiba (insulin degludec) Amber 6.1.1.2 Added strength (100 Amended 100units/ml inj Units/ml) as new, high strength formulation now also available (has same brand name) 10.07.15 Lantus (insulin glargine Green 6.1.1.2 Added strength (100 Amended 100 Units /ml) inj Units/ml) as new, high strength formulation now also available (has different brand name)
29.06.15 Sofosbuvir and ledipasvir Red 5.3.3.2 Specialist use only. Added tab For patients with cirrhosis meeting NHS England criteria for treatment of chronic Hepatitis C Date Drug and formulation Colour BNF Comments Action status section
29.06.15 Ombitasvir and Red 5.3.3.2 Specialist use only. Added paritaprevir and ritonavir For patients with cirrhosis tab meeting NHS England criteria for treatment of chronic Hepatitis C 29.06.15 Dasabuvir tab Red 5.3.3.2 Specialist use only. Added For patients with cirrhosis meeting NHS England criteria for treatment of chronic Hepatitis C 29.06.15 Daclatasvir tab Red 5.3.3.2 Specialist use only. Added For patients with cirrhosis meeting NHS England criteria for treatment of chronic Hepatitis C 29.06.15 Sofosbuvir tab Red 5.3.3.2 Specialist use only. Added, with TA NICE TA330 number
29.06.15 Tegafur and uracil cap Red 8.1.3 Discontinued by Removed manufacturers (2013) 29.06.15 Obinutuzumab inj Red 8.2.3 NICE TA343 Added, with TA number 29.06.15 Rifaximin tab [Targaxan] Amber 5.1.7 For hepatic encephalopathy. Added TA NICE TA337. number and 29.06.15 Omalizumab inj Red 3.4.2 NICEShared TA339 care guidance Addedbrand name.TA available (although needs numberChanged colour updating). from red to amber. 29.06..15 Ustekinumab inj Red 13.5.3 NICE(Note: TA340 remains non- Added TA formulary for other number indications) 29.06.15 Apixaban tab Green 2.8.2 NICE TA341 Added TA number, and colour for indication (treatment and secondary prevention of DVT/PE)
29.06.15 Darifenacin tab Green 7.4.2 First or second line option Added for urinary incontinence. Represents a more cost effective alternative to solifenacin (recommended in NICE CG171)
29.06.15 Cetraben ointment Green 13.2.1 Added
29.06.15 Vedolizumab inj Red 1.5.3 For ulcerative colitis. Added, with TA Specialist use only. number 29.06.15 Exenatide long-acting inj Green 6.1.2.3 AmendedNICE TA342 colour from amber Amended to green Date Drug and formulation Colour BNF Comments Action status section
29.06.15 Lixisenatide inj Green 6.1.2.3 Amended colour from amber Amended to green and removed 29.06.15 Dulaglutide inj Green 6.1.2.3 Notdirection a first to-line consider option, as but first - Added mayline for be newconsidered patients for patients with compliance problems or needle phobia, 24.06.15 Carmellose sodium eye Amber 11.8.1 Removedor for patients brand with name kidney Amended drops (preservative-free) impairment (see prescribing [Celluvisc] information and local guidelines).
04.06.15 Fortisip Bottle 200ml N/A 9.4 Moved from section 2 to Amended section 1 of UHS feeds and nutritional supplements formulary
03.06.15 Amsacrine inj Red 8.1.5 Product discontinued Removed 03.06.15 Ciclosporin eye drops/eye Red Unlicens Eye ointment for use if eye Amended ointment ed drops unavailable
03.06.15 Magnesium sulfate 20% Red Unlicens For use within maternity Added (10g in 50ml) inj ed.9.3.1 services at the Princess Anne Hospital, Southampton.
29.04.15 Rivaroxaban Amber 2.8.2 NICE TA335. Added TA Amber for prevention of number, added atherothrombotic events wording after ACS
29.04.15 Etoricoxib tab Amber 10.1.1 Removed wording (‘For bariatric surgery only’), amended colour 29.04.15 Simeprevir cap Red 5.3.3.2 Specialist use only. Amended NICE TA331 wording, added TA number
29.04.15 Golimumab inj Red 1.5.3 Specialist use only. Added BNF NICE TA329 section, wording and TA number
29.04.15 Infliximab inj Red 1.5.3 Specify brand. Added wording, NICE TA329 added TA number Date Drug and formulation Colour BNF Comments Action status section
29.04.15 Adalimumab inj Red 1.5.3 NICE TA329 Added TA number
29.04.15 Cinacalcet tab Red 9.5.1.2 Specialist use only. Added with TA NICE TA117 number
29.04.15 Aflibercept intravitreal inj Red 11.8.2 NICE TA305 Added TA Also for treatment of number and diabetic macular oedema additional indication 29.04.15 Empagliflozin tab Green 6.1.2.3 NICE TA336 Added with TA number
29.04.15 Levonorgestrel intra- Blue 7.3.2.3 Second-line option to Mirena Added uterine system [Jaydess]
25.03.15 Miconazole 100mg Green 7.2.2 Discontinued by Removed pessary manufacturer 25.03.15 Ethinylestradiol Blue 7.3.1 Gedarel 30/150 replaces Amended 30microgram and Marvelon desogestrel 150microgram [Gedarel 30/150]
25.03.15 Ethinylestradiol Blue 7.3.1 Gedarel 20/150 replaces Amended 20microgram and Mercilon desogestrel 150microgram [Gedarel 20/150] 25.03.15 Calcium-Sandoz liquid Green 9.5.1.1 Discontinued by Removed manufacturer 25.03.15 GlucoRx blood glucose Blue 6.1.6 Replaced by GlucoRx Nexus Removed test strips and Wavesense Jazz/Jazz Duo blood glucose test strips 25.03.15 GlucoRx Nexus blood Blue 6.1.6 Replaces GlucoRx blood Added glucose test strips glucose test strips
25.03.15 Wavesense Blue 6.1.6 Replaces GlucoRx blood Added Jazz/Wavesense Jazz Duo glucose test strips blood glucose test strips
25.03.15 Tapentadol oral solution Amber 4.7.2 Specialist recommendation Added only for breakthrough pain for patients taking tapentadol MR tabs
Date Drug and formulation Colour BNF Comments Action status section
25.02.15 Simeprevir caps Red 5.3.3.2 Specialist use only. For Added patients meeting NHS England eligibility criteria for treatment of Genotype 1 chronic Hepatitis C. 25.02.15 HyQvia (normal human Red 14.5.1 Adult immunology only. New Added immunoglobulin and second-line subcutaneous hyaluronidase) immunoglobulin.
25.02.15 Abacavir with lamivudine Red 5.3.1 Specialist use only Added and dolutegravir [Triumeq] tabs
25.02.15 Dolutegravir tabs Red 5.3.1 Specialist use only Added
25.02.15 Lithium carbonate MR Amber 4.2.3 Only to be used in Changed from tabs/lithium citrate liquid accordance with shared care green to amber guidelines
25.02.15 Liraglutide with insulin Red 6.1.2.3 Specialist use only Added degludec 25.02.15 Saxagliptin tabs Green 6.1.2 Replaced by alogliptin Removed
25.02.15 Alogliptin tabs Green 6.1.2 To replace saxagliptin Added
25.02.15 Dabigatran tabs Green 2.8.2 According to NICE TA 327 Added TA for the treatment and number secondary prevention of deep vein thrombosis and/or pulmonary embolism
28.01.15 Vitapro Powder Following formulary review Removed of feeds and nutritional supplements
28.01.15 Provide Xtra Following formulary review Removed of feeds and nutritional supplements 28.01.15 Maxijul Super Soluble Following formulary review Removed of feeds and nutritional supplements 28.01.15 Elemental 028 Powder Following formulary review Removed of feeds and nutritional supplements 28.01.15 Duocal Super Soluble Following formulary review Removed of feeds and nutritional supplements Date Drug and formulation Colour BNF Comments Action status section
28.01.15 Suplena Following formulary review Removed of feeds and nutritional supplements 28.01.15 Seravit Paediatric Powder Following formulary review Removed of feeds and nutritional supplements
28.01.15 Prosure Following formulary review Removed of feeds and nutritional supplements
28.01.15 Nepro Following formulary review Removed of feeds and nutritional supplements 28.01.15 Fortini Multifibre Following formulary review Removed of feeds and nutritional supplements
28.01.15 Vital 1.5 Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Peptamen HN Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Liquigen Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Ketocal powder Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fortisip Compact Protein Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fortisip Compact Fibre Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fortini Creamy Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fortimel Regular Section Following formulary review Added 2 of oral of feeds and nutritional nutrition supplements section Date Drug and formulation Colour BNF Comments Action status section
28.01.15 Paediasure Peptide Section Following formulary review Added 1 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fresubin Thickened Stage Section Following formulary review Added 2 1 of oral of feeds and nutritional nutrition supplements section 28.01.15 Fortini Smoothie Section Following formulary review Added 1 of oral of feeds and nutritional nutrition supplements section 28.01.15 Estradiol implants Discontinued by Removed manufacturer
28.01.15 Clinitest reagent tabs Discontinued by Removed manufacturer
07.01.15 Erythropoiesis- Red 9.1.3 According to NICE TA323 Changed TA 07.01.15(Decembe Imatinibstimulating tablets agents Red 8.1.5 According to NICE TA326 Adnumberded TA (December (epoetin and number rmeeting) darbepoetin) meeting) 07.01.15 Dabrafenib capsules Red 8.1.5 According to NICE TA321 Added (Decembe r meeting)
26.11.14 Dihydrocodeine MR Green 4.7.2 Changed from blue to green Changed 26.11.14 Tramadoltablets MR Green 4.7.2 Changed from blue to green Changed
26.11.14 Co-amilofruse tablets Green 2.2.4 Changed from blue to green Changed
26.11.14 Osvaren tablets Green 9.5.2.2 Changed from blue to green Changed
26.11.14 Co-codamol 30/500 Green 4.7.1 Changed from blue to green Changed tablets Date Drug and formulation Colour BNF Comments Action status section
26.11.14 Ibuprofen gel Green 10.3.2 Changed from blue to green Changed
26.11.14 Metformin sachets Discontinued by Removed manufacturer. Some wards now have strong tablet crushers to crush the tablets
20.10.14 Dimethyl fumarate Red 8.2.4 According to NICE TA320 Added 20.10.14 Lenalidomidecapsules capsules Red 8.2.4 According to NICE TA322 Added
20.10.14 Carbamazepine chewable Discontinued by Removed tablets (Tegretol manufacturer Chewtabs)
29.9.14 Buprenorphine patches Prescribe by brand name Note 29.9.14 Budesonide MDI Discontinued by Removed manufacturer
29.9.14 Adrenaline (epinephrine) Discontinued by Removed inhaler [Primatene Mist] manufacturer
1.9.14 Micafungin infusion Red 5.2.4 Micafungin is first-line Changed 1.9.14(August Domperidone Green Domperidoneechinocandin, cancaspofungin still be is Note (Augustmeeting) usedsecond for-line stimulation of meeting) lactation, following a restriction to its licensed 1.9.14 Generic sildenafil when Green 7.4.5 For men post-prostatectomy Note indications. Local (August required recommendation is 10mg meeting) three times a day for 7 to 10 days, then stop. Contra- indicated in patients with known cardiac problems
1.9.14 Sildenafil tablets Amber Not in Off-label use as an option in Added (August BNF for patients with Raynaud’s meeting) this phenomenon indicatio n Date Drug and formulation Colour BNF Comments Action status section
1.9.14 Choice of NRT patch Green 4.10.2 Change from NiQuitin CQ to Changed (August Nicorette Invisi patches meeting)
1.9.14 Minoxidil tablets Now 2.5.1 Change from red to amber Changed (August amber meeting) 1.9.14 Regadenoson injection Red Not in For use during radionuclide Added (August BNF myocardial perfusion meeting) scanning
1.9.14 Dabigatran capsules Now 2.8.2 VTE prophylaxis (hips and Changed (August red knees) change from amber meeting) to red 1.9.14 Co-amoxiclav dispersible Discontinued by Removed (August tablets manufacturer meeting) 1.9.14 Quinupristin with Discontinued by Removed (August dalfopristin injection manufacturer meeting) 1.9.14 Sodium fusidate injection Discontinued by Removed (August manufacturer meeting)
1.9.14 Brimonidine gel Green 13.6.3 For patients with rosacea Added (August who have failed to respond meeting) to, or are intolerant of, other options, or have 1.9.14 Canagliflozin tablets Green 6.1.2.3 psychologicalAccording to TA315 distress due to Added (August persistent redness. Cautious meeting) use is advised until more data are available around long-term safety and potential loss of effect with longer-term use. Some patients have noted a worsening of their rosacea after application
1.9.14 Prasugrel tablets Amber 2.9 According to NICE TA317 Changed TA (August number meeting) 1.9.14 Lubiprostone capsules Amber 1.6.7 According to NICE TA318 Added (August meeting) 1.9.14 Ipilimumab infusion Red 8.1.5 According to NICE TA319 Added (August meeting) Date Drug and formulation Colour BNF Comments Action status section
1.9.14 Enzalutamide capsules Red 8.3.4.2 According to NICE TA316 Added (August meeting) 1.9.14 Acetylcysteine tablets Amber 3.7 Remove ‘effervescent’ from Removed (August formulary entry meeting)
21.7.14 Prochlorperazine Discontinued by Removed 21.7.14 Trifluoperazinesuppositories MR Discontinuedmanufacturer by Removed capsule manufacturer
21.7.14 Artesunate IV Red No For severe or complicated P. Added mono- falciparum malaria graph in 21.7.14 Artemether and Red BNF5.4.1 For acute uncomplicated P. Added lumefantrine tablets falciparum malaria or as oral [Riamet] step-down treatment following IV artesunate 21.7.14 Emerade pre-filled pen Green 3.4.3 Supply problems with other Added brands of adrenaline for self- administration
21.7.14 Minims Word ‘Minims’ has been Amended replaced by ‘unit dose eye drops’ to allow purchasing of different brands
30.6.14 Dexmedetomidine Red 15.1.4.4 Off-label use for awake Added 30.6.14 Evrainfusion patch Blue 7.3.1 Thirdcraniotomy.-line option Added Patients to be informed of off-label status and lack of comparative evidence and that they can choose to have an alternative
30.6.14 Zoely tablets Blue 7.3.1 Third-line option. Consultant Added use only in Solent. 30.6.14 Alimemazine Amber 3.4.1 Off-label use for children Changed colour tablets/liquid with severe behavioural from red to insomnia amber
30.6.14 Afatinib tablets Red 8.1.5 According to NICE TA310 Added
30.6.14 Bortezomib injection Red 8.1.5 According to NICE TA311 Added TA number Date Drug and formulation Colour BNF Comments Action status section
30.6.14 Alemtuzumab infusion Red Not yet According to NICE TA312 Added in BNF 30.6.14 Alemtuzumab infusion Red 8.2.3 The old formulation of Added ‘named alemtuzumab, used for bone patient’ marrow transplant patients, 30.6.14 Didronel PMO isDiscontinued now only availabl by e as a Removed namedmanufacturer patient drug
30.6.14 Glyceryl trinitrate buccal Discontinued by Removed tablets manufacturer 30.6.14 Liothyronine sodium Amber 6.2.1 Shared care guideline not Changed from tablets required red to amber
30.6.14 Forceval Junior Soluble Green 9.6.7 Replace formulation Changed from Foreceval Junior capsules 30.6.14 Butrans patches Green 4.7.2 Included in previously toChanged Junior from agreed primary care Solubleamber to green guideline
30.6.14 Transtec patches Green 4.7.2 Included in previously Changed from agreed primary care amber to green guideline 30.6.14 Dapagliflozin tablets Green 6.1.2.3 To be used in line with NICE Changed colour TA288 from amber to green 30.6.14 Latanoprost preservative- Amber 11.6 For patients who are Added free eye drops intolerant of preservatives (Monopost)
2.6.14 ellaOne tablet Green 7.3.5 Wider use supported e.g Amended (May women with high BMI or 2.6.14 Quinine sulphate tablet Green 10.2.2 ‘300mg’ removed from Both 200 and meeting) intrauterine device is (May formulary entry for 300mg tablets declined or contra-indicated meeting) nocturnal leg camps are now (up to 120 hours after available for intercourse) this indication 2.6.14 Fluticasone furoate plus Green 3.2 Option for patients who Added (May vilanterol (Relvar Ellipta) cannot use other inhaler meeting) dry powder inhaler for devices. asthma Note: Fluticasone furoate is more potent than the propionate salt. Fluticasone furoate 92 micrograms once daily is approximately equivalent to 250 micrograms fluticasone propionate twice daily and the 184 micrograms once a day dose to propionate 500 micrograms twice a day
Date Drug and formulation Colour BNF Comments Action status section
2.6.14 Fluticasone furoate plus Green 3.2 Option in moderate to Added (May vilanterol (Relvar Ellipta) severe COPD. meeting) dry powder inhaler for COPD Note: Fluticasone furoate is more potent than the propionate salt. Fluticasone furoate 92 micrograms once daily is approximately equivalent to 250 micrograms fluticasone propionate twice daily
2.6.14 Metoclopramide No longer indicated as a Note new (May tab/liq/inj motility stimulant due to risk recommendatio meeting) of neurological adverse ns effects. See MHRA Drug Safety Update August 2013
2.6.14 Domperidone No longer indicated as a Note new (May tab/susp/suppos motility stimulant due to risk recommendatio meeting) of serious cardiac side ns effects. See MHRA Drug Safety Update May 2014
28.4.14 Aripiprazole IM depot Red 4.2.2 For use in secondary Added 28.4.14 Pixantroneinjection injection Red 8.1.2 Accordingpsychiatric to care. NICE Criteria TA306 for for Added nonuse -areHodgkin’s being developed lymphoma
28.4.14 Aflibercept injection Red 11.8.2 According to NICE TA305 for Added TA macular oedema (central number 28.4.14 Rituximab infusion Red 8.2.3 Accordingretinal vein to occlusion) NICE TA308 for Added TA anti-neutrophil cytoplasmic number antibody-associated vasculitis 28.4.14 Azathioprine suspension Amber 8.2.1/ Added 10.1.3
28.4.14 Forceval Soluble Green 9.6.7 For adult patients with poor Added effervescent tablets swallowing, who are nil by mouth or who require medicine administration through an enteral feeding tube. Product can be used orally or through a gastric or jejunal enteral feeding tube. May be suitable for patients who are at risk of refeeding syndrome, with poor wound Date Drug and formulation Colour BNF Comments Action status section
24.2.14 Zoledronic acid 5mg Red 6.6.2 Generic zoledronic acid is Amended 24.2.14 Fluocinoloneinfusion (generic) acetonide Red 11.4.1 Accordingnow available to NICE and canTA301 be for Added implant diusedabetic when macular clinicians oedema choose to prescribe off-label for patients with osteoporosis
24.2.14 Hyacyst (sodium Red Not in To be assessed and findings Added hyaluronate) bladder BNF reported back to DPC instillation (device) 24.2.14 Perampanel tablets Amber 4.8.1 Treatment initiated and Added patients stabilised by neurology specialists
24.2.14 Vesomni (tamsulosin plus Green Not yet For moderate to severe Added solifenacin) MR tablets in BNF storage and voiding symptoms associated with benign prostatic hyperplasia 24.2.14 Teriflunomide tablets Red Not yet inNICE men TA303 who arefor adultsnot with Added in BNF adequatelyactive relapsing responding-remitting to treatmentmultiple sclerosis with monotherapy
20.1.14 Bretylium injection 2.3.2 No longer used Removed 20.1.14 Zoledronic acid 4mg Red 6.6.2 In cancer care, IV zoledronic Amended injection acid will replace pamidronate and oral clodronate Date Drug and formulation Colour BNF Comments Action status section
16.12.13 Amoxicillin capsules Red 5.1.1.3 For patients with chronic low Amended 16.12.13 Fidaxomicin tablets Amber 5.1.7 Changeback pain from associated red to amber. with Amended Modic type 1 changes On advice of microbiology for first episode of severe C. 16.12.13 Magnesium oxide Amber 9.5.1.3 diffChange on concomitant from red to amber Amended capsules antibiotic or second episode
16.12.13 Magnesium Amber 9.5.1.3 Change from red to amber Amended glycerophosphate capsules/tablets 16.12.13 Apomorphine injection Red for 4.9.1 Existing patients need co- Amended new ordinated transfer to patient secondary care s 16.12.13 Linaclotide capsules Amber 1.6.7 According to local algorithm Added
16.12.13 Immediate release Green 7.4.2 Not suitable for frail older Added wording oxybutynin tablets women or patients with 16.12.13 Ribavirin tablets Red 5.3.3 Accordingcognitive impairment to NICE Amended TA300 (hepatitis C, children and young people)
16.12.13 Peginterferon alfa Red 5.3.3 According to NICE Amended injection TA300 (hepatitis C, children and young people)
16.12.13 Ranibizumab intravitreal Red 11.8.2 According to NICE TA298 Amended injection (choroidal neovascularisation [pathological myopia]) 16.12.13 Ocriplasmin intravitreal Red 11.8.2 According to NICE TA297 Added injection (vitreomacular traction)
25.11.13 Botulinum toxin Red 4.9.3 List of routinely Amended commissioned indications has been updated (see end of document)
28.10.13 Lisdexamfetamine Amber 4.4 For licensed indication Added 28.10.13 Mercaptopurinecapsules tablets Change 8.1.3 Shared care guideline on Changed colour from azathiorpine/mercaptopurine red to is available from amber http://www.westhampshirec cg.nhs.uk/medicines/healthc are-professionals
Date Drug and formulation Colour BNF Comments Action status section
30.9.13 Dibotermin alfa Now replaced by Opgenra Removed 30.9.13 Vitamins(Inductos) for age related Amber Not in Prescribed locally for Amended macular degeneration BNF patients with ‘category 4’ formulation (Viteyes 2 Formula AMD who have advanced 30.9.13 Buccal midazolam Red 4.8.2 Off-label use prior to Added capsules) disease in one eye only (Buccolam) endoscopy for a specific indication (advan ced lesions or visual group of adults and children acuity <20/32). ‘Viteyes 2 over 10 years who do not F ormula’ is the preferred tolerate IV cannulation (e.g. product as it is the least those with learning expensive and contains the difficulties). correct combination of IVvitamins midazolam and zinc. continue Unlikes to beprevious the first AMD line vitamins option for it thecan majoritybe given ofto patientsprevious or current smokers as it no longer contains beta- carotene. In patients with AMD categories 1 to 3 there is no convincing evidence to support prescribing currently, but patients may opt to purchase these OTC.
Prescribing of Viteyes 2 is normally initiated on secondary care advice. Patients should be reviewed regularly and ‘treatment’ discontinued if found to be of no benefit
30.9.13 Testosterone gel Amber 6.4.2 Only for proven Added (Testogel/Tostran) hypogonadism with marked clinical symptoms of testosterone deficiency
30.9.13 Infatrini Peptisorb Section Added (200ml) 3 of oral nutrition section 30.9.13 Paediasure Plus Juce Section Added (200ml, apple and very 3 of oral berry) nutrition section Date Drug and formulation Colour BNF Comments Action status section
2.9.13 Mirabegron tab Green 7.4.2 According to NICE TA290 Added NICE TA 2.9.13 Ceftaroline inj Red 5.1.2 Only for specialist use on Addednumber. the advice of microbiology Changed from amber to green
2.9.13 Eltrombopag tab Red 9.1.4 According to NICE TA293 Added
2.9.13 Eptotermin alfa Red Not in Replacement for Inductos Amended (Opgenra) for BNF for spinal surgery. Osigraft 2.9.13 Dapagliflozinimplantation tab Amber 6.1.2.3 Accordingremains the to formularyNICE TA288 Added choice for tibial surgery
2.9.13 Aripiprazole tab Amber 4.2.1 According to TA292 (bipolar Updated disorder in children)
2.9.13 Rivaroxaban tab Green 2.8.2 According to NICE TA287 Updated (pulmonary embolism and recurrent venous 2.9.13 5-aminolevulinic acid Red Not in Forthromboembolism) visualisation of Added (August (Gliolan) powder for oral BNF malignant tissue during meeting) solution surgery for malignant glioma
29.7.2013 Ketoconazole tab 5.2.2 No longer recommended for Note 29.7.2013 Norethisterone tablets Blue 7.3.2.1 Anfunga alternativel infections. to Femulen, Add (Noriday) whichSee press has releasebeen discontinued from byMHRA manufacturer 29.7.2013 Pripsen sachets Discontinued by Removed manufacturer
29.7.2013 Calcium carbonate Green 9.5.1.1 While Calcium Sandoz liquid Added effervescent tablets is unavailable (Cacit) 29.7.2013 Colistimethate powder for Red 5.1.7 According to NICE TA276 Added inhalation (Colobreathe) Date Drug and formulation Colour BNF Comments Action status section
29.7.2013 Hydroxyethyl starch Licence has been suspended Removed (Voluven) because large RCTs have reported an increased risk of renal dysfunction and mortality in critically ill or septic patients who received hydroxyethyl starch compared with crystalloids. See Drug Safety Update
24.6.2013 Tramadol MR Blue 4.7.2 Add to blue 24.6.2 013 Dihydrocodeine MR Blue(FP10 4.7.2 Addcategory to blue for (FP10use categoryprimary care for useonly) primary care only) 24.6.2013 Slow Sodium Amber 9.2.1.2 Change from red to amber
24.6.2013 Captopril liquid Amber 2.5.5 Change from red to amber 24.6.2013 Fidaxomicin tabs Red 5.1.7 Limited to patients with first Add episode of severe C diff 24.6.2013 Aflibercept inj Red 11.8.2 Forwhen wet concurrent age-related antibiotics macular Add degenerationcannot be stopped; according and tofor NICEsecond TA294 episodes of C diff. On advice of microbiology
24.6.2013 Paliperidone long-acting Red 4.2.2 For prescribing by Solent Change inj specialists (previously Southern Health only) 24.6.2013 Teriparatide inj Red 6.6.1 For treatment of atypical Change subtrochanteric fractures
24.6.2013 Omalizumab inj Red 3.4.2 According to NICE TA278 Update NICE TA number
24.6.2013 Ranibizumab injection Red 11.8.2 According to NICE TA283 Add NICE TA (macular oedema) number
24.6.2013 Pirfenidone caps Red 3.11 According to NICE TA282 Added Date Drug and formulation Colour BNF Comments Action status section
24.6.2013 Abatacept inj Red 10.1.3 According to NICE TA280 Update NICE (rheumatoid arthritis) TA number
20.5.13 Adcal chewable tab Green 9.5.1.1 Will replace Calcichew Changed 20.5.13 Adcal D3 effervescent tab Green 9.6.4 Will replace Calfovit sachets Changed
20.5.13 Adcal D3 chewable tab Green 9.6.4 Will replace Calcichew D3 Changed Forte
20.5.13 Adcal D3 caplets Green 9.6.4 Reserved for patients who Added cannot tolerate chewable or effervescent 20.5.13 Oxazepam tab Amber 4.10.1 For use according to the Added emergency department policy on alcohol misuse 20.5.13 Femulen 7.3.2.1 Has been discontinued Removed
29.4.13 Dabigatran cap Green 2.8.2 Previously amber for Changed 29.4.13 Rivaroxaban tab Green 2.8.2 Previouslyprevention amberof stroke for in Changed preventionpatients with of AF.stroke Changed in to patientsgreen as withGPs AF.don’t Changed refer to greenthese patientsas GPs don’t to a specialistrefer these patients to a specialist 29.4.13 Apixaban tab Green 2.8.2 NICE TA275 for prevention Added of stroke and systemic embolism in patients with non-valvular atrial fibrillation
29.4.13 Ranibizumab inj Red 11.8.2 NICE TA274 for diabetic Added macular oedema
29.4.13 Mirabegron tab Amber 7.4.2 Wording superseded by Added publication of NICE TA 29.4.13 Lixisenatide inj Amber 6.1.2.3 Consider as first-line GLP- Added receptor agonist for new patients instead of exenatide 29.4.13 Insulin degludec Amber 6.1.1.2 Initiated and stabilised by a Added (Tresiba) specialist for difficult to manage patients with type 1 29.4.13 Linagliptin tab Green 6.1.2.3 Fordiabetes patients with any stage Added of renal impairment
29.4.13 Tobramycin dry powder Red 5.1.4 NICE TA276 Added inhaler Date Drug and formulation Colour BNF Comments Action status section
29.4.13 Sevelamer carbonate Amber 9.5.2.2 When calcium-containing Added sachets products are not tolerated
29.4.13 Cerelle tab Green 7.3.2.1 Branded generic version of Added Cerazette
29.4.13 Octasa MR tab Amber 1.5.1 New name for Mesren Changed
29.4.13 Halothane Red 15.1.2 Has been discontinued Remove
25.2.13 Testosterone patch Blue 6.4.2 Had been discontinued, but Re-instated 25.2.13 Progesterone 8% vaginal Red 6.4.1.2 now available from a new Added gel supplier
25.2.13 Human menopausal Red 6.5.1 Added gonadotrophin inj ‘Menopur’ 25.2.13 Follitropin(Menopur) alfa inj Red 6.5.1 Added
25.2.13 Choriogonadotropin alfa Red 6.5.1 Added inj
25.2.13 Cetrorelix inj Red 6.7.2 Added
25.2.13 Buserelin inj Red 6.7.2 Added
25.2.13 Fluticasone and Green 3.1.1.1 Added formoterol inhaler 25.2.13 Ivacaftor(Flutiform) tab Red 3.7 Routinely commissioned for Added patients age 6 and over with cystic fibrosis and G551D mutation 25.2.13 Naltrexone tab (Adepend) Amber 4.10.1 For maintenance of Updated with abstinence in alcohol trade name dependence
25.2.13 Aclidinium bromide Green 3.1.2 Base prescribing decisions Added inhaler on which device the patient can use and cost 25.2.13 Glycopyrronium inhaler Green 3.1.2 Base prescribing decisions Added on which device the patient can use and cost
25.2.13 Voractiv tab Red 5.1.9 As complete courses of Added Voractiv. drugs for TB are managed 5.1.9 amended by the hospital, all drugs in section 5.1.9 of the formulary will become ‘red’
Date Drug and formulation Colour BNF Comments Action status section
25.2.13 Argatroban inj Red 2.8.1 An option for patients in Added critical care areas with heparin-induced thrombocytopenia (HIT)
25.2.13 Eplerenone tab Amber 2.2.3 To reduce the risk of Amended cardiovascular mortality and morbidity in selected patients with chronic heart failure 25.2.13 Ipilimumab infusion Red 8.1.5 According to NICE TA268 Added
25.2.13 Vemurafenib tab Red 8.1.5 According to NICE TA269 Added
25.2.13 Mannitol caps for Red 3.7 According to NICE TA266 Added inhalation
21.1.13 Ivabradine tab Amber 2.6.3 According to NICE TA267 Updated 21.1.13 Methylthioninium chloride Red Not in Blue Marker is to be used Added 1% inj (methylene blue) BNF during surgery. 21.1.13 Budesonide[Blue Marker] cap Amber 1.5.2 ForMethylthioninium ileo-caecal disease chloride Added brand [Budenofalk] 5mg/ml (methylene blue) [Proveblue] to be used for patients with methaemoglobinaemia
21.1.13 Darunavir liquid Red 5.3.1 GUM and Child Health Added specialists only 21.1.13 Naltrexone tab Amber 4.10.1 Now licensed for Updated maintenance of abstinence in alcohol dependence 21.1.13 Aluminium roll-on Green 13.12 Added [Andhydrol Forte]
21.1.13 Propantheline bromide Green 6.1.5 Previously in section 1.2 of Updated tab formulary. Now in 6.1.5 too, for use in patients with 21.1.13 Lysine/arginine 2.5% Red Not in Forhyperhidrosis renal protection during IV Added infusion BNF radionuclide DOTATATE therapy
21.1.13 Carbomer 980 Amber 11.8.1 To be used instead of Updated (polyacrylic acid) eye Geltears drops [Clinitas Gel] Date Drug and formulation Colour BNF Comments Action status section
21.1.13 Methylthioninium chloride Red Not in Blue Marker is to be used Added 12.12.12 1%Dimeticone inj (methylene lotion blue) Green BNF13.10.4 duringDue to surgery.supply problems with Updated [Blue(Hedrin) Marker] Methylthioniniummalathion aqueous chloride liquid, 5mg/mldimeticone (methylene lotion (Hedrin) blue) [Proveblue]has been changed to be used from forblue patientsto green with methaemoglobinaemia
12.11.12 Glatiramer injection Red 8.2.4 As part of the Department of Added Health’s risk sharing scheme for patients with multiple sclerosis
15.10.12 Alteplase injection Red 2.10.2 Update to NICE guidance for Change TA 15.10.12 Rilpivirine tablets Red 5.3.1 acute ischaemic stroke. Now numberAdded TA264
15.10.12 Prucalopride tablets Amber 1.6.7 According to shared care Updated 15.10.12 Jext auto-injector Green 3.4.3 Specialistguideline -(availableled managed from Added transferwww.hampshire.nhs.uk/ from Epipen to Jext (thisprimary device-care/ has a longer shelfRegister life) with NHS Hampshire for a password)
15.10.12 Iloprost infusion Red Unlicens For severe Raynaud’s Updated ed phenomenon secondary to systemic sclerosis, according to flowchart
15.10.12 Zostavax vaccine Red 14.4 Specialist prescribed in Added
secondary care for small
number of patients with severe, intractable, recurrent herpes zoster 15.10.12 Alphosyl HC cream 13.5.2 Discontinued Remove from
formulary
20.9.12 Varenicline tablets Green 4.10 Changed to green Date Drug and formulation Colour BNF Comments Action status section
17.9.12 Taurolidine IV Red Not in Used as a line lock in Added 17.9.12 Naltrexone tablets Amber 4.10the BNF Forpatients alcohol on addictionlong-term TPN Previously used or IV fluids at Southern, now also at 17.9.12 Sodium hyaluronate eye Amber 11.8.1 For patients with a proven UHSAdded drops (Hylo-Tear & Hylo- allergy to preservatives Forte)
17.9.12 Travoprost eye drops Amber 11.6 For patients with a proven Added allergy to benzalkonium chloride
17.9.12 Loteprednol eye drops Amber 11.4.1 Added
17.9.12 Ulipristal 5mg tablets Amber 6.4.1.2 An option for the pre- Added operative treatment of uterine fibroids. Consultant recommendation (no shared care guideline required) 17.9.12 Fluorouracil plus salicylic Green 13.8.1 For actinic keratosis. Can be Added acid cutaneous solution used in primary care. Efudix (Actikerall) remains the first-line topical treatment (awaiting update of Map of Medicine) 17.9.12 Ivabradine tablets Green 2.6.3 (wording removed - Added superseded by NICE guidance) 17.9.12 Betnovate N cream and Green 13.4 Dermovate NN has been Added ointment discontinued 17.9.12 Rivaroxaban tablets Green 2.8.2 NICE TA261 -an option for Added treating DVT and long-term secondary prevention
17.9.12 Botulinum toxin type A Red 4.9.3 Option for chronic migraine Added according to NICE TA260 17.9.12 Abiraterone tablets Red 8.3.4 An option for metastatic Added prostate cancer after testosterone reduction 17.9.12 Erlotinib tablets Red 8.1.5 therapyPossible andfirst -docetaxelline option in Added accordinglocally advanced to NICE or TA259 metastatic non-small-cell EGFR-TK mutation positive lung cancer according to NICE TA258 17.9.12 Dabigatran capsules Amber 2.8.1 Possible treatment to Added prevent stroke and systemic embolism in people with atrial fibrillation according to NICE TA249 Date Drug and formulation Colour BNF Comments Action status section
17.9.12 Calcitonin nasal spray 6.6 Being discontinued due to Removed risk of cancer
17.9.12 Buccal midazolam pre- Amber 4.8.2 To replace unlicensed Added filled syringes midazolam for children with 17.9.12 Prucalopride tablets Amber 1.6.7 Changeda seizure fromdisorder red to amber Changed 17.9.12 Ticagrelor tablets Green 2.9 NICE TA236 Changed colour
17.9.12 Rituximab infusion Red 8.2.3 NICE TA226 Added 17.9.12 Bivalirudin injection Red 2.8.1 NICE TA230 Added
17.9.12 Thalidomide capsules Red 8.2.4 NICE TA228 Added
17.9.12 Phenobarbital elixir Red 4.8.1 Unlicensed special order Added preparations are available, with and without alcohol as an excipient. Specialist only prescribing and supplied 17.9.12 Bortezomib injection Red 8.1.5 fromNICE hospitalTA228 pharmacies Added
17.9.12 Apixaban tablets Red 2.8.2 NICE TA245 Added
17.9.12 Nilotinib capsules Red 8.1.5 NICE TA241 Added
18.6.12 Indapamide tablets and Green 2.2.1 Added 18.6.12 Calcitoninprolonged -nasalrelease spray tablets Red 6.6 (wording removed – product Added now discontinued)
18.6.12 Omalizumab injection Red 3.4.2 Although ‘red’ locally it was Added
agreed that in order to reduce day case attendances the 6 local patients receiving this medication may be considered for SC administration in primary care as an interim measure, prior to teaching self- administration to these patients, by GP agreement. Prescribing responsibility will be retained by the specialists long term, with future consideration of a homecare supply service once patients are happy to self-administer Date Drug and formulation Colour BNF Comments Action status section
18.6.12 Telaprevir tablets Red 5.3.3.2 According to NICE TA252 Added
18.6.12 Boceprevir capsules Red 5.3.3.2 According to NICE TA253 Added
18.6.12 Nilotinib capsules Red 8.1.5 According to NICE guidance Added (TA251) as an option for first line treatment of chronic myeloid leukaemia 18.6.12 Standard dose imatinib Red 8.1.5 According to NICE TA251 as Added an option for first line treatment of chronic myeloid leukaemia
18.6.12 Tocilizumab injection Red 10.1.3 According to NICE guidance Updated TA247 for rheumatoid arthritis
18.6.12 Tobramycin dry powder Red 5.1.4 For specialist use for Added inhaler selected patients e.g active patients, stable patients 18.6.12 Bee venom (Pharmalgen) Red 3.4.2 According(superseded to byNICE NICE TA246 Added TA276)
18.6.12 Fingolimod capsules Red 8.2.4 Only according to NICE Added TA254
18.6.12 Proveblue injection Red 15.2 Licensed version of Added methylthioninium chloride 18.6.12 Collagenase injection Red 10.3.1 Only for use in a very specific Added (Xiapex) cohort of patients, in line with current low priorities guidance, i.e. flatten their fingers or palm on a table; and there is functional impairment. One cord, 2 joints up to 90% flexion. Only to be administered by hand surgeons trained in its use. Restricted to cases where it is likely that only a single injection of Xiapex will be Date Drug and formulation Colour BNF Comments Action status section
18.6.12 Rituximab injection Red 10.1.3 According to agreed guidance Added for adults with systemic lupus erythematosus
18.6.12 Exenatide long-acting Amber 6.1.2.3 NICE TA248 Added injection
18.6.12 Growth hormone Red 6.5.1 First line choices are Omnitrope Updated and Genotropin. Consider 18.6.12 Pioglitazone tablets Green 6.1.2.3 Prescribeswitching generically.existing adult Although Updated thepatien licensedts on other indications options for to brandedOmnitrope and or generic Genotropin versions are different, due solely to patent protection issues, generic pioglitazone has demonstrated bioequivalence with the branded version 18.6.12 Estradiol valerate plus Red 7.3.1 Specialist recommendation only Added dienogest (Qlaira) tablets on an exceptional basis for heavy menstrual bleeding 18.6.12 Tapentadol prolonged- Amber 4.7.2 Third or fourth line niche use, Added release tablets following specialist recommendation only 18.6.12 Paliperidone long-acting Red 4.2.2 Specialist prescribing only at Added injection Southern Health 18.6.12 Fluticasone furoate nasal Green 12.2.1 Second or third line for patients Added spray who need a different device
2.5.12 Rivaroxaban tablets Red 2.8.2 Off-label use for patients with Added 2.5.12 Prilocaine 2% injection Red 15.2 fractured neck of femur or who Added have a plaster cast and who fulfil the assessment criteria
26.3.12 Midodrine tablets Green 6.1.5 Missed off formulary previously Added 26.3.12 Laxido Green (unlicens1.6.4 Previously ‘blue’ but now Changed 27.2.12 Estradiol vaginal tablet Green ed)7.2.1 changed to ‘green’ to promote Changed 10 micrograms use in UHS for adults with from blue to chronic constipation or faecal impaction Date Drug and formulation Colour BNF Comments Action status section
green 27.2.12 Quetiapine MR tab 4.2.1 Use immediate-release tablets Removed 27.2.12 Goserelin, leuprorelin, Amber 6.7.2 The least costly gonadorelin Changed triptorelin and analogue over the course of 8.3.4.2 treatment and for the organisation administering it should be used for its licensed indications 27.2.12 Simeticone oral Red 1.1.1 For use during endoscopy Added suspension 27.2.12 Easyhaler Formoterol Green 3.1.1.1 Added 27.2.12 Nevirapine MR tablets Red 5.3.1 Added 27.2.12 Rotigotine patches Amber 4.9.1 Initiated/recommended by Changed specialists: as a replacement for oral dopamine agonists in patients with inadequate control of nocturnal/early morning symptoms; in patients with inadequate compliance of complex regimens (cognitive problems, unable to swallow oral medication, motor problems) and as sole treatment in emergency situations when patients are unable to swallow oral drugs 27.2.12 Exenatide long-acting Amber 6.1.2.3 (wording removed - superseded Added injection by NICE guidance) 27.2.12 Interferon alfa 2a eye Red Not in For specialist use only Added drops BNF 27.2.12 Sterile talc kit Red Not in For specialist use only Added BNF 27.2.12 Rituximab injection Red 8.2.3 NICE TA243 – follicular Added lymphoma 27.2.12 Tocilizumb injection Red 10.1.3 NICE TA238 - systemic, Added juvenile, idiopathic arthritis 21.2.12 Dabigatran capsule Amber 2.8.2 Changed to 110mg and 150mg amber
23.1.12 Dabigatran capsule Red 2.8.2 (wording removed - superseded Added 110mg and 150mg by NICE guidance) 23.1.12 PelvicToner device Blue As part of pelvic floor training Added
23.1.12 Levonorgestrel tablet 30 Blue 7.3.2.1 For existing patients Added microgram 23.1.12 Ticagrelor tablet Blue 2.9 NICE TA236 Added 23.1.12 Mifamurtide injection Red 8.2.4 NICE TA235 Added 23.1.12 Estradiol vaginal tablet Blue 7.2.1 Added 10 micrograms 23.1.12 Nicorette Icy White Gum Green 4.10.2 As part of smoking cessation Added 4mg and 2mg programme Date Drug and formulation Colour BNF Comments Action status section
23.1.12 Nicorette Quickmist Green 4.10.2 As part of smoking cessation Added 23.1.12 mouthsprayNicorette Inhalator Green 4.10.2 programmeAs part of smoking cessation Added programme 23.1.12 Capsaicin patch 8% Red 10.3.2 Only for patients with post- Added herpetic neuralgia who have inadequate pain relief with other options 3.1.12 5% sodium chloride Green 9.2.2 Added infusion (Polyfusor) 12.12.11 Aminophylline MR tablet Green 3.1.3 For existing patients Added 12.12.11 Ferric carboxymaltose inj Red 9.1.1.2 Added 12.12.11 Levobupivacaine inj Red 15.2 Until 31 March 2012, additional Added 0.125% (200ml bags) indication of peripheral nerve infusion via peripheral nerve block catheter
14.11.11 Dexamethasone Red 11.4.1 NICE TA229 Added 14.11.11 Golimumab injection Red 10.1.3 NICE TA233 Added intravitreal implant 14.11.11 Moxifloxacin tablet Amber 5.1.12 Already on the formulary for Amended restricted use. Formulary entry to be amended to add use according to guideline (adult ENT)
17.10.11 TriRegol tablet Blue 7.3.1 To replace Logynon Added 17.10.11 Rigevidon tablet Blue 7.3.1 To replace Ovranette Added 17.10.11 Millinette 30/75 tablet Blue 7.3.1 To replace Femodene Added
12.09.11 Ciclosporin eye drops Red 11.8.1 A special Added 12.09.11 Golimumab injection Red 10.1.3 NICE TA225 Added
12.09.11 Retigabine tablets Amber 4.8.1 NICE TA232 Added
12.09.11 Botulinum A toxin Red 4.9.3 Restricted use. Specify which Added injection (Xeomin brand) brand of botulinum is required and indication
19.07.11 Oxycodone (Oxynorm) NOT Oxycodone (Oxynorm) capsule NOT ON capsule ON will no longer be stocked in FORMULA FORM- Pharmacy. RY ULARY Any patients prescribed Oxycodone (Oxynorm) capsule will be changed to Oxycodone (Oxynorm) liquid (green) in accordance with the formulary. Patients may continue to bring their supply of Oxycodone (Oxynorm) capsules inline with Trust’s Medicines Policy 19.07.11 Golimumab injection Red 10.1.3 NICE TA220 Added Date Drug and formulation Colour BNF Comments Action status section
19.07.11 Romiplostim Red 9.1.4 NICE TA221 Added injection 19.07.11 Naftidrofuryl capsule Green 2.6.4 NICE TA223 Added
19.07.11 Denosumab injection Amber 6.6.2 NICE TA204 Added
19.07.11 Naltrexone tablet Amber 4.10.1 Maintaining abstinence after Amended alcohol withdrawal in patients with alcohol dependence. (Unlicensed indication). To be recommended by the alcohol detox service 19.07.11 Tamoxifen liquid Amber 8.3.4.1 Reserved for patients unable to Amended swallow tablets
13.06.11 Raltegravir tablet Red 5.3.1 Prescribing should be carried out be local HIV specialists only 13.06.11 Maraviroc tablet Red 5.3.1 Prescribing should be carried out be local HIV specialists only 13.06.11 GlucoRx test strips Blue 6.1.6 13.06.11 Osvaren tablet Blue 9.5.2.2 Hyperphosphataemia of chronic 13.06.11 Evicel sealant Red 2.11 Specialistrenal failure use in only. patients Remove Amended statementundergoing “for dialysis pancreatic and liver surgery only” 09.05.11 Fondaparinux injection Red 2.8.1 As an adjunct to thrombolysis Amended with tenecteplase in STEMI patients 09.05.11 Darunavir 400mg tablet Red 5.3.1 Indicated for treatment Amended experienced adults
18.04.11 Azacitidine injection Red 8.1.3 NICE TA218 - myelodysplastic Added syndromes 18.04.11 Saxagliptin tablet Green 6.1.2.3 Another option for Type 2 Added Diabetes. Can be used in patients with moderate to severe renal impairment 21.03.11 Gedarel tablet Blue 7.3.1 Alternative to Mercilon and Added. Marvelon whilst in short supply Amended June 2011 to correct colour = blue 18.04.11 Pazopanib tablet Red 8.1.5 According to NICE TA215 Added 18.04.11 Bendamustine injection Red 8.1.1 NICE TA216 – lymphocytic Added leukaemia 18.04.11 Abatacept infusion Red 10.1.3 NICE TA195. Rheumatoid Added arthritis - drugs for treatment after failure of a TNF inhibitor 18.04.11 Sirolimus tablet Amber 8.2.2 Prevention of rejection in post Amended liver transplant patients 18.04.11 Rosiglitazone tablet Green 6.1.2 Withdrawn from the UK Market Removed Date Drug and formulation Colour BNF Comments Action status section
November 2010 21.03.11 Cefoxitin injection Red 5.1.2.1 Not licensed. Added Microbiology approved 21.03.11 Dovobet Gel Green 13.5.2 Topicaltreatment Treatment of mycobacterium of scalp Amended psoriasis.abcessus respiratoryTopical treatment infection of in mildcystic to fibrosis moderate “non scalp” plaque psoriasis. Dermatology only. Dovobet ointment already on formulary 21.03.11 Efavirenz solution Red 5.3.1 HIV infection. Alternative to Amended tablets in patients with NG tubes or paediatric patients. Tab and caps already on formulary 21.03.11 Liraglutide injection Green 6.1.2.3 {previously amber} Amended 21.03.11 Exenatide injection Green 6.1.2.3 {previously amber} Amended 21.03.11 Venlafaxine tablet Green 4.3.4 Only high dose is amber Amended {previously all doses amber} 21.03.11 Fluorouracil cream Amber 13.8.1 Previously red Amended
21.03.11 Aripiprazole tablet Amber 4.2.1 NICE TA213 Prescribing in 15- For 17 year old: schizophrenia information 21.03.11 Prucalopride tablet Red 1.6 NICE TA211 For (Resolor®) information 21.03.11 Nutricia Pre-op Red 9.4 Carbohydrate loading of Amended carbohydrate drink® patients prior to surgery on enhanced recovery programme
21.02.11 Nifedipine MR Green 2.6.2 Added 21.02.11 Coractentablet/capsule capsule Green 2.6.2 Removed
21.02.11 Denosumab injection Red 6.6.2 According to NICE TA204 Added
21.02.11 Tafluprost eye drops Amber 11.6 Specialist use and Added recommendation. Reserved for patients who 21.02.11 Melatonin tablet/capsule Amber 4.1.1 Cost effective first line choice is Amendment require preservative free Biomelatonin tabs, followed by prostaglandin eye drops, e.g. Melatonin Life extension caps for patients with corneal grafts and Melatonin Biotec caps
21.02.11 Peristeen Anal Irrigation Green 1.6.5 Reserved for patients with Added systems neurogenic bowel dysfunction e.g. after spinal cord injury when other treatments have failed, or when incontinence is a 21.02.11 Liraglutide injection Amber 6.1.2.3 Accordingproblem to NICE TA203 For Information 21.02.11 Gefitinib tablet Red 8.1.5 According to NICE TA192 21.02.11 Trastuzumab injection Red 8.1.5 Gastric cancer according to For NICE TA208 Information
Date Drug and formulation Colour BNF Comments Action status section
13.12.10 Colecalciferol capsule Green 9.6.4 Added 13.12.10 Botulinum Toxin Indications agreed for NHS For Indications Hampshire only. See Last page information of cumulative update
05.11.10 Fortisip bottle 200ml Section 9.4 Remove: Neutral Amended 3 Add: Strawberry, vanilla and Dietitia banana n Keep: chocolate request 16.11.10 Tocilizumab injection Red 10.1.3 NICE TA Added
18.10.10 Pollinex Quattro® Red 3.4.2 Reserved for Specialist allergy Added injection clinic’s use only 18.10.10 Rosiglitazone tablet Green 6.1.2.3 MHRA alert. Removed from UK Removed market 21.10.10 18.10.10 Etonogestrel implant Blue 7.3.2.2 Only to be inserted and Added (Nexplanon®) removed by trained professionals 18.10.10 Etonogestrel implant Blue 7.3.2.2 No longer available Removed (Implanon®)
18.10.10 Calcium phosphate Green 9.6.4 Alternative to calcium and Added sachet (Calfovit D3®) vitamin D3 forte for patients unable to swallow tablets 18.10.10 Dronedarone tablet Amber 2.3.2 According to NICE TA197 Added
18.10.10 Fondaparinux injection Red 2.8.1 For NSTEMI (NICE CG94) Amended 18.10.10 Nutricia Pre-op Red 9.4 Carbohydrate loading of Amended carbohydrate drink® patients prior to elective primary total hip replacement on enhanced recovery programme 18.10.10 Polyacrylic acid eye drops Amber 11.8.1 Remove brand name Amended {Geltears®} 13.09.10 3,4- diaminopyridine Red 10.2.1 For Lambert Eaton Myasthenic Remains on tablet Syndrome formulary 13.09.10 Nebusal® (7% sodium Green 3.7 Recommended by specialist for Added chloride solution for cystic fibrosis. nebulisation) Prescribe by brand
13.09.10 Carmellose sodium 0.5% Green 11.8.1 Less expensive than single use Added eye drops (Optive®) carmellose drops (Celluvisc®) when allergy to commonly used preservatives is problematic 13.09.10 Prucalopride tablet Red 1.6 (wording removed - superseded Added (Resolor®) by NICE TA211) 13.09.10 Abidec® drops Green 9.6.7 Used by neonatal unit as an Added alternative to Dalivit drops 13.09.10 Insuman Comb25® (with Green 6.1.1.2 Alternative to Mixtard 30® Added ClickStar pen) Date Drug and formulation Colour BNF Comments Action status section
13.09.10 Vinorelbine capsule Red 8.1.4 Reserved for patients with poor Added venous access as part of a second or third line 13.09.10 Human Mixtard 30® vial Green 6.1.1.2 Discontinuedchemotherapy December regimen. 2010In all Removed and 3ml cartridge other circumstances, and for exceptional cases, an Individual 18.07.10 NuvaRing® contraceptive Blue 7.3.1 3Fundingrd or 4th Request line option may be Added device appropriate 18.07.10 Insulatard InnoLet® Green 6.1.1.2 Treatment of gestational Added diabetes and type 2 diabetes in pregnancy 18.07.10 Darunavir 400mg tablet Red 5.3.1 In combination with ritonavir for Added antiretroviral naïve patients 18.07.10 Beractant Red 3.5.2 Added (Survanta®) suspension 18.07.10 Sugammadex injection Red 15.1.7 Consultant Anaesthetist use Added only. To be used in line with “Protocol for use of sugammadex” 14.06.10 Methylprednisolone tablet Green 6.3.2 Treatment of relapse in multiple Added sclerosis (previously methylprednisolone sodium succinate powder for injection was administered orally) 14.06.10 Ritonavir tablet Red 5.3.1 Added
14.06.10 Ritonavir capsule Red 5.3.1 Removed
14.06.10 Prochlorperazine buccal Green 4.6 As an alternative to injectable Amended tablet antiemetics 14.06.10 Apraclonidine Red 11.8.2 Laser surgery Added 1% single use eye drop units
26.04.10 Remifentanil injection Red 15.1.4.3 Patient controlled analgesia for Amended labour (previously theatres only) 26.04.10 Stalevo® tablet Amber 4.9.1 Parkinson’s disease Added
26.04.10 Levofloxacin 0.5% eye Red 11.3.1 Following corneal graft surgery. Added drops Complete course to be provided on discharge 26.04.10 Levofloxacin 0.5% unit Red 11.3.1 Following corneal graft surgery if Added dose eye drops instillation is greater than 6 times daily. Complete course to be provided on discharge from hospital 26.04.10 Certolizumab pegol Red 10.1.3 Option in severe active Added injection rheumatoid arthritis if already tried methotrexate and another DMARD, according to NICE: http://guidance.nice.org.uk/TA18 6 Date Drug and formulation Colour BNF Comments Action status section
26.04.10 Trabectedin injection Red 8.1.5 Soft tissue sarcoma according to Added NICE: http://guidance.nice.org.uk/TA18 5 26.04.10 Ferrous fumarate tablet Green 9.1.1.1 Currently PCT use only, change Amended to green 26.04.10 Ferrous sulphate Green 9.1.1.1 Replaced by ferrous fumarate Removed 26.04.10 Triclofos liquid Red 4.1.1 Discontinued Removed 26.04.10 Amphotericin lozenges Green 12.3.2 Discontinued Removed End of list
Basingstoke, Winchester & Southampton District Prescribing Committee Portsmouth Area Prescribing Committee Botulinum Toxin Indications Routinely Commissioned Licensed: Dysport Botox Xeomin NeuroBloc Blepharospasm √ √ √ Cervical dystonias √ √ √ √ Focal spasticity √ (arm & foot) √ (foot & post stroke wrist/hand) √ (post stroke arm) Hemifacial spasm √ √ Hyperhidrosis (severe) √ Migraine prophylaxis √ Neurogenic detrusor over- √ activity Incontinence due to subcervical √ spinal cord injury or multiple sclerosis Unlicensed: Ophalmology Induction of ptosis to treat corneal exposure problems or facial palsy Treatment of early onset squint EMG guided intra ocular inj for diagnostic purposes such as checking for binocular potential prior to squint surgery EMG guided intra ocular inj for therapeutic purposes such as inj into medial rectus & transpose vertical recti for cases of complete VI nerve palsy Synkinetic facial movements Treatment of crocodile tears
Surgery Anal Fissure
Neurology Paravertebral & shoulder muscle spasm Pyriformis syndrome Foot dystonia in Parkinsons Disease Face & neck tics Axial dystonia
ENT Frey’s Syndrome Laryngeal & tongue dystonia Cricopharyngeal spasm Vocal Cord Granuloma Severe drooling/hypersalivation Masseteric hypertrophy & associated facial pain Spasm of reconstructed pharynx after laryngectomy Spastic dysphonia Focal dystonia & muscle spasm of head and neck
Gastro Oesphageal spasm Achalasia (oesophageal motility disorder) Sphincter of Oddi dysfunction
Approved by Basingstoke, Southampton & Winchester DPC and Portsmouth APC 2013
(9.13)